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Abstract 
 
To determine the potential of histamine H3 receptor (H3R) ligands as new 
antiepileptic and procognitive drugs, aromatic ether derivatives (1-12) belonging to 
the nonimidazole class of ligands, with high in-vitro binding affinity at human H3R, 
were tested for their in-vivo anticonvulsive activity in maximal electroshock (MES)-, 
pentylenetetrazole (PTZ)-, and strychnine (STR)-induced seizure models in male 
adult rats having phenytoin (PHT) and valproic acid (VPA) as the reference 
antiepileptic drugs, pitolisant (PIT) as the standard H3R antagonist/inverse agonist, 
and donepezil (DOZ) as a reference procognitive drug. Among the H3R ligands (1-
12) tested in the current project,  H3R antagonist 4 showed significant and dose-
dependent reduction in the duration of tonic hind limb extension (THLE) subsequent 
to acute systemic administration (5, 10, and 15 mg/kg, i.p.). Importantly, the 
protective action observed for H3R antagonist 4 in MES-induced seizure was 
comparable to that of the reference antiepileptic drug phenytoin (PHT), and was also 
reversed when rats were pretreated with the CNS penetrant pyrilamine (PYR) (10 
mg/kg, i.p.), or with the selective H3R agonist R-()-methylhistamine (RAMH) (10 
mg/kg, i.p.). Furthermore, the procognitive studies indicate that acute pre-training 
systemic administration of H3R antagonist 4 (2.5 mg/kg, i.p.) facilitated acquisition, 
whereas pre-testing acute administration of 4 (5 and 10 mg/kg, i.p.) improved 
retrieval. Interestingly, the procognitive effect of 4 on retrieval was completely 
abrogated when rats were pretreated with the centrally-acting H2R antagonist 
zolantidine (ZOL) but not the centrally acting H1R antagonist PYR, indicating that 
histaminergic pathways through activation of H2Rs appear to be participating in 
neuronal circuits involved in the retrieval processes. Taken together, our results show 
that H3R antagonist 4 demonstrates anticonvulsant properties in the MES-induced 
viii 
 
seizure model and improves cognitive performance through actions on different 
memory stages. Therefore, H3Rs may have implications for the treatment of 
degenerative disorders associated with impaired memory function and may represent 
a novel therapeutic pharmacological target to tackle cognitive problems associated 
with the chronic use of antiepileptic drugs.  
 
Keywords: Histamine H3 receptors, Antagonists, Anticonvulsant, Learning, 
Memory, Passive avoidance test, R-()-methyl-histamine, Pyrilamine, Zolantidine  
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 )cibarA ni( tcartsbA dna eltiT
 
المستخلقة حديثًا على نماذج  3-دراسة فعالية عدد من مثبطات مستقبلات الهستامين
 فصيلة معينة من القوارض فيالذاكرة ضعف بحثية مختلفة للصرع و
 صالملخ
يعتبر العلاج . الصرع هو مرض مزمن ويعد من احد الأمراض العصبية الأكثر انتشاًرا
 70-70لكن أدوية الصرع المتوفرة حاليًا فعالة لدى . الدوائي أهم وسائل المعالجة لهذا المرض
من الحالات مازالت مستعصية بالإضافة للأعراض %  70-70من المرضى عوًضا عن أن % 
تم أجراء الكثير من الدراسات . لهذه الأدوية خاصة تلك التي تصيب الذاكرةالجانبية المصاحبة 
  R3H( 0-مؤخًرا حول صنف جديد من العلاجات الدوائية يسمى مثبطات مستقبلات الهستامين
 )tnasilotiP( .لاستكشاف تأثيرها على كثير من الأمراض العصبية والسلوكية )stsinogatna
للدراسات السريرية، وقد تخطى مراحل  وصولا 0-يعتبر من أول مثبطات مستقبلات الهستامين
لذلك قمنا في دراستنا هذه . متقدمة في كثير من هذه الدراسات بما فيها الصرع، وضعف الذاكرة
ولها نسبة ارتباط ثثبيطي عالية   )tnasilotiP(ومشتقة من ) 01-1(باستخدام  مركبات مختلفة 
هدف هذه الرسالة البحثية هو  :الأهداف. كما تشير الدراسات المخبرية 0-تقبلات الهستامينبمس
ضعف للصرع وsledom( (دراسة فعالية هذه المركبات المستخلقة حديثًا على عدة نماذج بحثية 
 المقارنة، لغرضعوًضا عن ذلك و. (ratsiW)الذاكرة على ذكور الجرذان البالغة من فصيلة 
قمنا أيضا بفحص تأثير مركبات مستخدمة حاليا من قبل مرضى الصرع أو ضعف الذاكرة وهي 
بداية قمنا بدراسة تأثير هذه المركبات، . )lizpenoD(و ))dicA ciorplaV، )niotynehP(
باستخدام ثلاث نماذج بحثية مختلفة، على نوبات الصرع الناتج عن الصدمات الكهربائية 
أو  eninhcyrtS(( أو تلك الناتجة عن مواد كميائية وهي إما) )kcohs cirtcele lamixaM
اعتمادًا على فعاليتها في تقليل أو منع هذه النوبات، تم اختيار أفضل هذه . lozartetenelytneP((
 x
 
 :النتائج. )tset ecnadiova evissaP(الذاكرة باستخدام  ضعف المركبات لفحص تأثيرها على
تميز  4لكن المركب . لاحظنا اختلاف تأثير هذه المركبات على نماذج الصرع البحثية المختلفة
بتأثيره القوي إحصائيًا على نوبات الصرع الناتجة عن الصدمات الكهربائية بحيث شابه تأثيره 
 71( عند الجرعة  )tnasilotiP(وللكن كان أشد فاعلية إحصائيًا مقارنة ب  )niotynehP(تأثير 
هذا التأثير اعتمد على الهستامين كناقل عصبي حيث تم إبطال هذا ). كيلوجرام/ ميليجرام
ومثبط  )enimatsihlyhtem -α-R(  0-المفعول باستخدام كل من منشط مستقبلات الهستامين
. اختلف تأثير هذا المركب على مراحل التعلم أو الذاكرة .)enimaliryP( 1-مستقبلات الهستامين
حّسنت إحصائيًا وبشكل كبير أحد مراحل الذاكرة المسماة ) كيلوجرام/ ميليجرام 2.0( فالجرعة
لم يكن معتمدا على الهستامين كناقل عصبي حيث أن كًلا  هذا التأثير. )noitisiuqca(بالاكتساب 
 )eniditnaloZ( 0-ومثبط مستقبلات الهستامين )enimaliryP( 1 -من مثبط مستقبلات الهستامين
 71و  2(، كان لكل من الجرعتين في المقابل. 4إبطال مفعول هذه الجرعة من المركب  فشل في
فاعلية كبيرة إحصائيًا في تقوية مرحلة أخرى من الذاكرة تسمى ) كيلوجرام/ ميليجرام
بواسطة ) كيلوجرام/ميلجرام 71(الجرعة وتم إبطال مفعول  )laveirteR(بالاسترجاع 
اعتمد على الهستامين   يمكن القول بأن تأثير هذه الجرعةتأسيًسا على ذلك،  .)eniditnaloZ(
في : الخاتمة. 0-كناقل عصبي تحديدًا من خلال تفاعل الهستامين مع مستقبلاته العصبية
له خصائص مضادة لنوبات الصرع الناتجة عن  4المحصلة، نتائجنا أظهرت أن المركب 
ته على تحسين الذاكرة من خلال تأثيره على مراحل الصدمات العصبية هذا بالإضافة لقدر
كون لها تطبيقات مستقبلية في علاج تقد  0-لذلك فإن مثبطات مستقبلات الهستامين. مختلفة منها
الذاكرة المصاحبة لكثير من أدوية  ضعف مرض الصرع تحديدًا لتجنب أو معالجة مشاكل
 .  ذاته حد في الصرع المستخدمة حاليا أو المصاحبة لمرض الصرع
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  ضعف الذاكرة الصرع، نوبات ،0-مثبطات مستقبلات الهستامين :مفاهيم البحث الرئيسية
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Chapter 1: Introduction 
 
1.1 Histamine as a central neurotransmitter 
Brain histamine (Figure 1) is a story that dates back to the early 20
th
 century 
when first-generation antihistamines were introduced at the time even before 
histamine H1 or H2 receptors (H1-2Rs) were known. Sedation, a central side effect 
associated with early antihistamines, raised speculation about a role for histamine in 
the brain, particularly in regard to wakefulness. Kwiatkowski (1943) was the first to 
isolate histamine from brain extract, mainly from the cortex. Later, 
electrophysiological studies in several brain regions and behavioural studies with 
intracerebroventricular (i.c.v.) infusion of histamine demonstrated a potential new 
neurotransmitter to be added to the existing neurotransmitter systems (Haas et al., 
2008). Furthermore, activity of neuronal histidine decarboxylase (HDC), histamine 
synthesizing enzyme, which was known to exist in nerve endings, decreased in many 
brain regions after lesions of the lateral hypothalamus (Garbarg et al., 1976, 
Schwartz et al., 1976).  
 
Figure 1: Chemical structure of histamine: 2-(1H-imidazol-4-yl) ethanamine 
 
The breakthrough in the field of neuronal histamine was the production of 
antibodies against HDC and histamine that were used to draw the first map of 
neuronal histamine pathways utilizing histochemical methods (Watanabe et al., 1983, 
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Panula et al., 1984). There are two storage compartments of brain histamine, one in 
the synaptic vesicles of neuronal endplates and one in the mast cells (Verdiere et al., 
1975). Both compartments equally contribute to the levels of brain histamine since 
W/W
V
 knockout mice, in which  mast cells are absent, lack around 50% of brain 
histamine compared to their wild counterparts (Maeyama et al., 1983). W/W
V
 
knockout studies and administration of 48/48 (Verdiere et al., 1975), a selective 
histamine releaser from mast cell granules,  can be used to differentiate between the 
two histamine pools. Through their contact with the brain side of the blood brain 
barrier, brain mast cells gate the interplay between the nervous, vascular and immune 
systems. Their amounts decrease with age and vary between species, sex, and 
pathological conditions (Silver and Curley, 2013). 
1.2 Localization and projections of histaminergic neurons 
Cell bodies of histamine neurons are confined in one area of the posterior 
hypothalamus called tuberomammillary nucleus (TMN), i.e. between the 
mammillary bodies and the optic chiasm of the tuber cinereum. Unlike other 
aminergic neurons with separate nuclei, histaminergic cell bodies send projections to 
different brain areas without a topographical pattern of their projections as confirmed 
with retrograde tracers. One perikyra can send descending and ascending extensions 
(Brown et al., 2001, Haas et al., 2008). Histamine neurons are heterogeneous 
demonstrating distinct control mechanisms and innervating different brain regions 
(Blandina et al., 2012). Histamine neurons are heterogeneous de Human brain 
contains 64000 histamine neurons (Haas et al., 2008), 16 times higher than that in 
rats, 4000 neurons (Ericson et al., 1987).  Histaminergic neurons send their 
ascending and descending pathways to the cerebrum, brain stem and spinal cord, 
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respectively (Figure 2). Through their extensions, histaminergic neurons rarely form 
the classical synaptic contact with their targets. Instead,  histamine is released from 
varicosities, i.e. swellings along the axon, and spreads to the surrounding area like a 
local hormone (Figure 3) affecting neuronal and non-neuronal components (Brown et 
al., 2001, Haas et al., 2008).  
Brain regions differ in amount of histaminergic fibers that they receive. 
Ventrally, histaminergic neurons highly innervate the hypothalamus, diagonal band, 
septum and olfactory tubercle. Amygdale, periventricular nuclei of the hypothalamus 
and hippocampal subiculum, and the dentate gyrus receive the largest amount of 
histaminergic fibers through the dorsal pathway. Other areas, like the cerebral cortex, 
striatum, nucleus accumbens, tend to be moderately innervated. The Substantia nigra 
and ventral tegmentum have more projections compared to the locus coeruleus and 
raphe nuclei. Generally, the descending pathway incorporates the least fiber densities 
(Brown et al., 2001). 
Figure 2: Projections of TMN histamine neurons. Two ascending pathways: 1) ventral 
part to the hypothalamus and septum, 2) dorsal part to the thalamus, hippocampus, 
amygdala, and forebrain. One descending pathway to the brain stem, cerebellum and 
spinal cord. Adopted from (Die Entwicklung von. (2010). Histamin-H3-
Rezeptorliganden als potenzielle Arzneistoffe und bildgebende pharmakologische 
Werkzeuge (unpublished doctoral thesis).  Institute for Pharmaceutical Chemistry, 
Medcinal Chemistry Division, Goethe University, Frankurt/Main, Geramny). 
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1.3 Biosynthesis, release, and metabolism of central histamine 
Histamine cannot pass through the blood brain barrier; thus it has to be 
biosynthesized in situ. A dietary amino acid precursor of histamine is L-histidine can 
pass through L-amino acid transporters (Figure 3) to the cerebrospinal fluid (CSF) 
pool and the cytoplasm of neurons. Therefore, histamine biosynthesis depends on the 
presence of this amino acid. Accordingly, L-histidine is converted to histamine 
through oxidative removal of a carboxyl group by a specific enzyme, HDC, EC 
4.1.1.22. At high concentration, histidine can be a substrate for nonspecific 
decarboxylase (Prell et al., 1996). The nonspecific synthesis pathways can be 
revealed with alpha-fluoromethyl histidine (α-FMH), an inhibitor of specific HDC. 
Once synthesized, histamine is packed in vesicles in both soma and varicosities 
through   vesicular monoamine transporter-2 (VMAT-2).  Upon depolarization of the 
histamine neuron, calcium-dependent release of histamine occurs (Verdiere et al., 
1975). Histamine biosynthesis and release in the CNS is modulated by the  histamine 
H3  auto-receptors (H3Rs) through cAMP/PKA-dependent pathways (section 1.4.3) 
(Bongers et al., 2007). Moreover, firing of central histaminergic neurons and release 
of histamine is also controlled by inputs and receptors of other systems including 
acetylcholine, norepinephrine, serotonin, and orexin among others (Brown et al., 
2001). Unlike other aminergic neurotransmitters, histamine has no known re-uptake 
mechanism (Brown et al., 2001). However, the central action of histamine is 
terminated via methylation by histamine N-methyltransferase (HNMT) in the 
extracellular space to yield N
tele
-methylhistamine which is then degraded by 
monoamine oxidase B to t-methyl-imidazole acetic acid (Prell et al., 1996, Brown et 
al., 2001, Haas et al., 2008). 
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1.4 Histamine receptors  
The precise effects of histamine are exerted through stimulation of four 
different G-protein coupled receptor (GPCR) subtypes, namely H1-H4R (Figure 4) 
(Arrang et al., 1988; Arrang et al., 1987; Arrang et al., 1983, 1985a; Hill, 1990; Hill 
et al., 1997; Lovenberg et al., 1999).  All histamine receptors, to varying levels, 
display constitutive activity (Bakker et al., 2000), i.e. have an active conformation 
state that is independent of any ligand binding. Whereas H1-3Rs are highly 
expressed in the brain. H4Rs  have low expression, if any, in the CNS (see Schneider 
and Seifert, 2015). 
 
Figure 3: Neuronal histamine biosynthesis, release and metabolism in the CNS. 
Adopted from (Haas et al., 2008). 
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1.4.1 Histamine H1Rs in the Central Nervous System 
H1R is coupled to the Gq/11 signaling pathway and has mainly excitatory 
effects. However, inhibitory effects through calcium-induced activation of potassium 
conductance are also possible. Furthermore, H1R is associated with formation of 
arachidoinc acid (AA) and nitric oxide (NO) that can act as a retrograde messenger 
controlling activity of pre-synaptic neurons however, the signaling pathway is yet to 
be clarified (Brown et al., 2001, Haas et al., 2008). 
H1Rs are primarily localized in brain regions involved in arousal and 
cognition including the thalamus, cortex, cholinergic nuclei in the mesopontine 
tegmentum and basal forebrain, aminergic nuclei in the locus corelus and raphe 
nuclei, septal nuclei, hippocampus, and amygdale. Also, H1Rs exist in high density 
in the nucleus accumbens, molecular layer of the cerebellum, nuclei of the cranial 
nerves, area postrema, and nucleus tractus solitaries (Brown et al., 2001). 
Interestingly, experimental studies with H1R KO mice have elucidated 
abnormal circadian rhythm of locomotor activity (i.e. more active at light cycle), 
Figure 4: Schematic illustration of main signaling pathways of human histamine 
receptors hH1-4R. Modified after Strasser et al., 2015 (Sadek and Stark, 2015). 
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reduced exploratory activity in a novel environment, reduced anxiety and 
aggressiveness, tapered pain sensitivity in different tests, selective changes in 
different memory tests. The latter observations shed light on the importance of  
histaminergic neurotransmission through central H1Rs. (Inoue et al., 1996, Yanai et 
al., 1998, Mobarakeh et al., 2000, Dai et al., 2007b, Dere et al., 2008). 
1.4.2 Histamine H2Rs in the central nervous system 
The H2R is coupled to a Gs protein and is thus involved in the cAMP/PKA/ 
cAMP response element-binding protein (CREB) signaling pathway producing 
excitatory effects like those observed in the CA1 region of the hippocampus, 
pyramidal cells and thalamic neurons (Figure 4).  
The H1- and H2Rs are colocalized in hippocampal pyramidal and granule 
cells, and aminergic nuclei (locus coeruleus, raphe nuclei, substantia nigra, ventral 
tegmental area). Further, H2Rs are present in high density in the basal ganglia and 
amygdala. However, the receptor distribution is limited in the septal nuclei and the 
hypothalamus where H1Rs predominate (Brown et al., 2001). Previous studies have 
shown that H2R KO mice suffered test-specific cognitive dysfunction accompanied 
by impaired hippocampal long-term potentiation (LTP) (Dai et al., 2007b). 
1.4.3 Histamine H3Rs in the central nervous system 
The H3R was discovered in 1983 in Paris using traditional pharmacology 
(Schwartz, 2011). Its molecular sttructure was revealed almost a decade later in 
efforts to identify an orphan GPCR that has widespread expression in the CNS 
(Lovenberg et al., 1999). Employing genetic information from human H3R and RT-
PCR technology, many isoforms are obtained from alternative splicing of the human 
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H3R gene as well as other species. These isoforms displayed heterogeneous 
pharmacology, signal transduction, and distribution in the CNS (Drutel et al., 2001, 
Hancock et al., 2003, Esbenshade et al., 2008), and will be further discussed below. 
Human H3R (hH3R) protein sequence displays high homology to hH4R [38-58%] 
(Liu et al., 2001, Morse et al., 2001, Zhu et al., 2001), however, very low homology 
(21-22%) compared to hH1- and hH2Rs (Lovenberg et al., 1999). 
As observed with other GPCRs in vitro, H3Rs display constitutive activity. 
This activity was noted in vivo at normal physiological levels, unlike other GPCRs 
(Morisset et al., 2000). GPCRs exist in equilibrium between their inactive and active 
conformations. The quantity of the active conformations and how effectively they 
couple to G-protein dictates the level of constitutive activity of the receptor. Inverse 
agonists are agents that stabilize the inactive state and thus inhibit the constitutive 
activity. 
Although H3Rs do exist in the periphery (Ichinose et al., 1990, Taylor and 
Kilpatrick, 1992, Imamura et al., 1995, Sugimoto et al., 2004, Hough and Rice, 
2011), it has predominant, heterogeneous expression in the CNS (Lovenberg et al., 
1999). High densities of the H3Rs were found in the rostal part of the rat cerebral 
cortex, hippocampus, amygdala, nucleus accumbens, striatum, olfactory tubercles, 
cerebellum, substantia nigra, and brain stem. In addition, rat H3Rs were moderately 
expressed in the hypothalamus and the cell bodies of histamine neurons (Panula et 
al., 2015). In humans, H3Rs are found mainly in the basal ganglia, globus pallidus, 
hippocampus and cortex (Martinez-Mir et al., 1990). This distribution is in concert 
with their function in controlling the firing of histamine neurons and modulating the 
synthesis and release of histamine as well as the release of other neurotransmitters 
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including dopamine, serotonin, norepinephrine, acetylcholine, -aminobutiric acid 
(GABA) and glutamate (Panula et al., 2015).  
The H3R is a member of the GPCR family. Through the α-subunit of the Gi/o 
protein (Gi/oα), H3Rs are negatively coupled to adenylate cyclase (Figure 4 and 5) 
(Hancock et al., 2003, Bongers et al., 2007, Panula et al., 2015). In addition, H3Rs 
were found to reduce intracellular calcium by Gi/oα-mediated suppression of N- and 
P-type calcium channels in dissociated TMNs (Takeshita et al., 1998). There is a lack 
of evidence supporting the coupling of H3R to inwardly rectifying potassium 
channels as is the case for other autoreceptors. Therefore, the aforementioned Gi/oα-
mediated reduction in calcium influx seems to explain the observed histamine-
induced inhibition of its own as well as other neurotransmitter release (Brown et al., 
2001, Hancock et al., 2003, Panula et al., 2015). 
Also, reduced intracellular calcium was postulated to be the direct effector in H3R 
agonist-induced reduction of norepinephrine release from noradrenergic nerve 
terminals in the myocardium (Silver et al., 2002). The G-protein βγ-subunit of H3Rs, 
Figure 5: Different possible signaling pathways of H3Rs. Adopted from (Bongers et al., 
2007). 
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with  possible complex interactions with other GPCRs, can activate other signaling 
pathways including mitogen-activated protein kinase (MAPK), Akt/ glycogen 
synthase kinase 3β (GSK3β) and phospholipase A2 (PLA2) (Figure 5) that are 
involved in neuronal plasticity and brain disorders (Bongers et al., 2007, Panula et 
al., 2015). 
In contrast to H1- and H2R genes, H3R gene has many “species-distinct” 
splice variants that result in the formation of a large number of isoforms (20 in 
human) (Esbenshade et al., 2008). The isoforms include the supersized form [e.g. 
hH3R (453) or rH3R (449)], the wild-type [445 amino acid] and the rest have shorter 
protein sequences [e.g. hH3R (453), hH3R (220)] (Hancock et al., 2003). Eight of the 
20 isoforms (in human) have been shown to be functional in heterogeneous 
expression systems including [hH3R (445), (453), (415), (413), (409), (373), (365) 
and (329)] (Esbenshade et al., 2008). Other H3R isoforms are either unstudied or 
expected to be non-functional since they lack important domains essential for ligand 
binding, carry a detrimental stop codon, or couldn’t assemble to a tertiary structure. 
However, these functionally inert isoforms could have a physiological role by 
altering the expression of other isoforms or changing the activity of other receptors 
or proteins (Hancock et al., 2003, Bongers et al., 2007). 
Different domains of H3R receptor (or any other GPCRs) have roles in 
affinity to H3R ligands, efficacy in coupling to a variety of signal transduction 
pathways or constitutive activity (Hancock et al., 2003, Arrang et al., 2007). Shorter 
H3R isoforms, with deletion in various domains of the receptor, could have 
dissimilar affinity or response to different H3R ligands. These dissimilarities are 
augmented with differential distribution of these receptors in different brain regions 
as indicated by real time- polymerase chain reaction (RT-PCR) studies (Bongers et 
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al., 2007, Esbenshade et al., 2008). For example, compared to shorter isoforms, rat 
H3R (rH3R) (445) appears to have more effective coupling to MAP kinase pathways, 
which are important for synaptic plasticity. Interestingly, the same isoform has a 
preferential localization in the hippocampus, a memory consolidation center (Drutel 
et al., 2001). Thus, selective H3R (445) ligands would be more applicable in 
cognitive disorders, like Alzheimer’s disease (AD).  
Knockout studies have demonstrated Electroencephalography (EEG)-
confirmed enhanced vigilance and increased arousal during behavioral tests 
including environmental change, locomotion and motivation tests (Gondard et al., 
2013), and general reduction of locomotor activity (Toyota et al., 2002) in H3R KO 
mice. These H3R KO mice displayed sleep restriction (Gondard et al., 2013), and 
loss of sensitivity to waking action of H3R antagonists and to memory impairing 
effects of scopolamine (Toyota et al., 2002). Total absence of H3R was advantageous 
in terms of cognition and reduced anxiety in response to avoidable stimuli (Rizk et 
al., 2004). 
1.4.4 Histamine H4Rs 
Similar to H3Rs, these receptors are coupled to Gi/o protein yet, unlike H3Rs, 
they are primarily expressed in the periphery (Zhu et al., 2001). Homology between 
H3- and H4Rs, as mentioned above, results in pharmacological similarities between 
the two receptors mainly with imidazole-containing compounds (Lim et al., 2005, 
Haas et al., 2008). H4Rs are largely engaged in immunomodulation and their 
expression predominates in cells and tissues of the immune system and by alteration 
of their levels in response to inflammatory stimuli (Zampeli and Tiligada, 2009). 
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1.5  Brain histamine in physiological and pathological conditions  
In agreement with widespread projection of its neurons and several signaling 
pathways coupled to its receptors, neuronal histamine is involved in multiple CNS 
actions. Brain histamine modulates several homeostatic functions like 
thermoregulation, fluid balance, energy metabolism and stress. Histamine, also, 
orchestrates biological rhythms, different behavioral states and higher brain activities 
like cognition (Brown et al., 2001, Haas et al., 2008). In this section, some selected 
histamine functions are described.  
1.5.1 Epilepsy  
Seizures are clinical manifestations of excessive excitation and abnormally 
enhanced  synchrony of  neurons in a restricted  region or in different parts of the 
brain (Fisher et al., 2005).  Epilepsy is a group of disorders characterized by a high 
predisposition to recurrent seizures. The etiology of epilepsy can be due to genetic, 
congenital, metabolic factors or secondary to stroke, trauma, tumors, drugs, alcohol 
or medications. Mechanistically, these change intrinsic (e.g.; pumps, ion channels, 
transporters) activity, alter synaptic transmission or cause “re-wiring” of neurons 
resulting in reduced seizure threshold. 
One of the main available strategies of pharmacotherapy for epilepsy is to 
correct the imbalance between excitatory, glutamate, and inhibitory, GABA, 
neurotransmission (Meldrum, 1995, Loscher, 2002, Stephen and Brodie, 2011). The 
central histaminergic system in many studies has been shown to reduce or protect 
from seizures. In preclinical studies, i.c.v. histamine prevented different types of 
seizures (Table 1). Inhibition of N-methyltransferase, the histamine metabolizing 
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enzyme in the CNS, by metoprine increased brain histamine content and reduced 
seizure susceptibility (Tuomisto and Tacke, 1986, Onodera et al., 1992a, Kakinoki et 
al., 1998, Yawata et al., 2004). Conversely, α-FMH, that diminishes histamine 
synthesis, increased seizure activity (Zhang et al., 2003b). Similarly, HDC KO mice 
were more prone to seizures (Hirai et al., 2004).  
H1Rs seem to be the key mediators of histamine-induced elevation of seizure 
threshold since centrally-acting H1R antagonists were shown to induce a 
proconvulsant effect in several models (Yokoyama et al., 1996, Zhang et al., 2003b). 
The proconvulsant action of H1R antagonists was prevented by histidine not 
physostigmine indicating the involvement of histaminergic mechanisms (Kamei et 
al., 2000).  H1R KO mice showed faster responses to amygdaloid and 
pentelyenetetrazole (PTZ)-induced kindling (Chen et al., 2003, Hirai et al., 2004). 
Clinically, children with febrile seizures had lower CSF histamine than those with 
fever but no convulsions, suggesting an anti-seizure effect of histamine (Kiviranta et 
al., 1995, Takano et al., 2010). Moreover, it has been found that H1R antagonists 
increased the incidence of seizures in children (Miyata et al., 2011).  
 Table  1: Preclinical studies of H3R antagonists in different epilepsy models 
 Electrically-induced 
seizures 
Chemically-induced 
seizures 
Genetically-
encoded seizures 
Histamine 
(i.c.v.) 
↓ Amygdaloid-kindled 
in rats
b
 
↓ PTZ-induced in micea  
Thioperamide  ↓ Amygdaloid-kindled 
and maximum electric-
shock in rats
d,e
 
↓ PTZ-induced in micec ↓ EL micef 
Clobenopropit ↓Amygdaloid-kindled in ↓ PTZ-induced in ratsg  
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 Electrically-induced 
seizures 
Chemically-induced 
seizures 
Genetically-
encoded seizures 
rats 
d,h
 
Pitolisant ↓ Maximum electric-
shock in mice
i 
↓ KA-induced 
hippocampal discharges 
(EEG) in mice
i
 
↓spike-and-wave 
discharges (EEG) in 
the GAERS*
i
 
ABT-239  ↓KA-induced in micej  
↓= Inhibit, reduce or delay seizures. PTZ= pentylenetetrazole, KA = Kianic Acid. *GAERS = 
genetic absence epilepsy rats from Strasbourg. 
a
Yokoyama et al. (1994). 
b
Kamei (2001). 
c
Vohora 
et al. (2000). 
d
Kakinoki et al. (1998). 
e
Harada et al. (2004). 
f
Yawata et al. (2004). 
g
Zhang et al. 
(2003a). 
h
Kamei and Okuma (2001).
 i
Kasteleijn-Nolst Trenite et al. (2013). 
j
Bhowmik et al. 
(2014).  
Furthermore, abnormal levels of H1Rs around the focus of epileptic injury in 
complex partial seizures were observed in human positron emission tomography 
(PET) studies (Tuomisto et al., 2001).  
1.5.2 Arousal and sleep-wake cycle 
Histaminergic neurons follow circadian rhythm in their firing and histamine 
release. Their activity peaks at high vigilance state and diminishes during sleep 
(Brown et al., 2001, Haas et al., 2008). TMN histaminergic neurons have a mutual 
inhibitory interaction with the ventrolateral preoptic nuclei (VLPO), which is 
involved in sleep regulation (Williams et al., 2014). The sedative effect of general 
anesthetics is postulated to depend on GBAB-mediated inhibitory pathways from 
VLPO to TMN neurons (Nelson et al., 2002, Moore et al., 2012). Histaminergic 
neurons also receive  excitatory input (through orexin and glutamate as a co-
transmitter) from orexin neurons, which are involved in arousal (Schone et al., 2014). 
Narcoleptic dogs with mutant orexin receptor-2 have lower histamine levels in their 
thalami and cortices (Nishino et al., 2001). Furthermore, TMN neurons have 
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reciprocal interaction with other aminergic nuclei (involved in cortical activation). 
Bilateral removal of the posterior hypothalamus leads to hypersomnia (Brown et al., 
2001). Interestingly, lower CSF histamine levels are observed in narcoleptic patients 
(Nishino et al., 2009). 
Pharmacologically, i.c.v. administration of histamine, H1R agonists, and oral 
thioperamide (causes increase in histamine levels) promotes wakefulness or EEG 
desynchronization. Their action is blocked by H1R antagonists. This suggests an 
H1R dependence of this function supported by a lack of effect of selective H2R 
antagonists in the sleep-wake cycle. Depletion of brain histamine by HDC inhibitor, 
α-FMH, increased sleeping time (Brown et al., 2001, Haas et al., 2008). Similarly, 
HDC KO displayed inability to stay awake in a new environment, a decreased EEG 
activation during waking, and an increased paradoxical sleep (Parmentier et al., 
2002). 
1.5.3 Cognition 
Cognition is not just learning and memorizing. It, also, includes several 
higher brain functions including attention, reasoning, problem solving and decision 
making. The cognitive process is not controlled by certain parts of the brain but 
rather it involves complex interactions between cortical and subcortical neuronal 
pathways. Cognitive impairment may involve one or more aspects of cognition. For 
instance, AD, a neurodegenerative disorder, is characterized by memory deficit while 
attention is impaired in attention-deficit hyperactivity disorder (ADHD). 
Schizophrenia is associated with impairment of executive function, i.e. cognitive 
inflexibility (Esbenshade et al., 2008).   
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In order to evaluate cognitive processes, many tests have been developed to 
analyze specific domains of cognition in animals as well as in clinical trials. In 
memory tests, animals are trained or habituated to a certain environment or behavior 
(utilizing fear or reward) during training sessions. Later during test sessions, animals 
are reintroduced to the same environment and observed for signs of recall (test 
session). For example, in contextual fear conditioning (CFC), animals receive a foot-
shock in a novel environment during training sessions. During test sessions, animals 
are returned to the same environment and a characteristic freezing behavior appears 
as an indication of recall. Active (AVT) and passive (PAT) avoidance tests use foot-
shock as an unpleasant consequence associated with a stimulus (light/sound) or an 
intrinsic dark preference, respectively. PAT and ACT assess long-term memory. 
Social recognition and object recognition tasks are short term memory tests that rely 
on the animals ability to recall familiar olfactory cues (social interaction) or test 
objects, respectively. In spatial memory tasks, animals are conditioned to link an 
object, reward or punishment to a particular place (e.g., Barnes maze, water maze 
and radial maze). Attentional set-shifting assays examine the animals ability to learn 
and re-learn (cognitive flexibility). Attention is analyzed by 5-trial inhibitory 
avoidance (5-trial IA) and 5-choice serial reaction time (5-CSRT) tests (Esbenshade 
et al., 2008). Some behavioral tests in clinical trials share similarities to these animal 
studies but take into account the complexity of the human brain. For pharmacological 
testing, agents or lesions may be applied to induce deficiency in a region or a system 
of the brain and to produce a memory deficit model. Scopolamine for example 
induces memory impairment through an effect on cholinergic transmission (Flood 
and Cherkin, 1986). Memory deficit can be introduced in animal strains through 
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genetic manipulation as is the case for transgenic APPTg2576 mice, a model of AD 
(McGowan et al., 2006).  
Several preclinical studies indicate a role for histamine neurotransmission in 
the cognitive process. In a previous study, inhibition of histamine synthesis in the 
brain by α-FMH was found to reduce social recognition in rats (Prast et al., 1996). In 
contrast, histamine (i.c.v.) facilitates memory in several tasks (Table 2). Moreover, 
impairment of performance in several memory tests has been observed in mice 
lacking H1- or H2Rs (Dai et al., 2007b, Dere et al., 2008). The selective H1R agonist 
2-(3-(trifluoromethyl)-phenyl)histamine, through i.c.v. administration, enhanced 
object recognition (Malmberg-Aiello et al., 2003). Clinically, the H1R antagonist 
negatively influenced attention (Okamura et al., 2000). H1R binding was shown to 
progressively decline in AD patients compared to their old, normal counterparts 
(Higuchi et al., 2000). Similarly, postmortem AD brains had low histamine content 
in the hypothalamus, hippocampus and temporal cortex (Mazurkiewicz-Kwilecki and 
Nsonwah, 1989, Panula et al., 1998). H3R KO mice had enhanced place recognition 
in the Barnes maze (Rizk et al., 2004). These mice were also resistant to 
scopolamine-induced amnesia in PAT (Toyota et al., 2002). In parallel, the selective 
H3R agonist RAMH increased forgetfulness in different memory models (Table 2). 
Table  2: Preclinical behavioral characterization of H3R agonists and antagonists 
 
Recognitio
n memory 
Spatial 
memory 
Working 
memory 
 
Long-term 
memory 
(fear 
memory) 
Executive 
memory 
Attention/ 
impulsivity 
Histamine 
(i.c.v.) 
↑ rats1,a ↑ rats2,b ↑ rats3,c ↑in rats1,d   
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RAMH ↓ in rats1,e   ↓ in rats1,e   
Thioperamid
e 
↑ rats1,4,a, f ↑ rats and 
mice
2,b, g
 
↑ ratsh ↑ mice 
1,2,3,4,f, i, j 
 ↑ SHR 
pups
k
 
Ciproxifan ↑ rats1,2,l ↑in mice2,g    ↑ SHR 
pups and 
rats
1,m, n
 
Pitolisant ↑ mice1,2,o   ↑ mice1,3,p   
GSK189254 ↑rats1,q ↑ in aged 
rats
1,q
 
 ↑ rats1,q ↑ rats1,q  
SHR = spontaneously hypertensive rats (attention deficit). ↑= increase or improve, ↓= decrease 
or worsen.  
1
Naïve animals, 
2
scopolamine-induced memory deficit, 
3
Dizocilpine-induced 
memory deficit, 
4
PTZ-induced memory deficit. 
a
(Prast et al., 1996). 
b
(Chen and Kamei, 2000). 
c
(Huang et al., 2003). 
d
(de Almeida and Izquierdo, 1986). 
e
(Blandina et al., 1996). 
f
(Jia et al., 
2006). 
g
(Komater et al., 2005). h=(Orsetti et al., 2002). 
i
(Meguro et al., 1995). 
j
(Charlier et al., 
2013). 
k
(Komater et al., 2003). 
l
(Pascoli et al., 2009). 
m
(Fox et al., 2002). 
n
(Day et al., 2007).
 
o
(Ligneau et al., 2007). 
p
(Brabant et al., 2013). 
q
(Medhurst et al., 2007).                       
1.5.4 Synaptic plasticity 
In the process of memory formation, molecular and cellular changes occur to 
enforce synapses that are essential for memory. These changes are called synaptic 
plasticity and involve activation or inhibition of receptors, ion channels and proteins 
with consequent alternation in the size and number of synapses (Middei et al., 2014). 
Long-term potentiation (LTP) and long-term depression (LTD) are forms of synaptic 
plasticity. The hippocampus is a brain structure that is highly involved in memory 
consolidation and the most studied region in this regard. 
Histamine was found to induce LTP in the CA1 region of the hippocampus in 
vitro in the absence of any external tetanus stimulation that is usually employed in 
such experiments (Selbach et al., 1997). On the other hand, impairment of 
electrically-induced LTP was demonstrated in vitro in the CA1 region of H1 and H2 
KO mice (Dai et al., 2007b). Such facilitation of synaptic activity could be attributed 
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to: 1) activation of kinases like PKA (through H2R and potentiated by H1R) and 
PKC (through H1R) and subsequent activation of other proteins, 2) mobilization of 
intracellular Ca
+2
 stores by inositol triphosphate (IP3) (through H1R), 3) H1-
mediated removal of Mg
+2
 block from NMDA receptors and subsequent Ca
+2
 influx 
and 4) H2R-mediated blockage of leak K
+
 conductance and increase of burst 
discharges in CA3 with  enhancement of its inputs to the CA1 (Brown et al., 2001, 
Haas et al., 2008). 
1.5.5 Locomotor activity and exploratory behavior 
An important component of animal activity is locomotion, i.e. movement 
from one place to another. It can be affected by many factors including external 
stimuli (like introduction to a novel environment) or internal physiological 
characteristics such as the circadian rhythm (Bevins and Besheer, 2001, Tosini, 
2007). Impairment of locomotor activity is associated with several disorders 
including Parkinson’s and Huntington’ diseases and hyperactivity syndrome. CNS 
drugs can affect locomotion which can influence other behavioral parameters 
including memory.  
In several studies, histamine was found to enhance locomotion. Depletion of 
brain histamine through pharmacological tools using α-FMH in ICR mice or by 
genetic methods (HDC-KO) reduced novelty-induced or spontaneous locomotor 
activity, respectively (Onodera et al., 1992b, Sakai et al., 1992, Kubota et al., 2002).  
Sakai et al. (1992) demonstrated that higher brain histamine is associated with 
increased locomotion. H1R KO mice showed impaired spontaneous activity (dark), 
exploration, and rearing in a new environment (Inoue et al., 1996). Recently, it has 
been shown that selective activation of histamine neurons increases locomotion (Yu 
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et al., 2015).  Moreover, previous results demonstrated that some H3R antagonists 
increased the release of histamine and tendency to increased locomotion (Ghi et al., 
1998, Mohsen et al., 2014).   
Contrary, depletion of histamine by α-FMH (in ICR mice but at higher dose: 
100 mg/kg) was reported to increase locomotor activity and rearing (at night time) 
which was accompanied by an 85% decrease in brain GABA (Sakai et al., 1995). In 
addition, the imidazole-based H3R antagonist thioperamide  was shown to decrease, 
to various degrees, amphetamine/apomorphine/cocaine-induced hyperactivity, an 
effect that was inhibited by the selective H3R agonist, namely (R)-α-methylhistamine 
RAMH (Clapham and Kilpatrick, 1994). Indeed, the methamphetamine’s 
hyperactivity effects were more pronounced in HDC-KO mice (Kubota et al., 2002). 
Moreover, H1R antagonism increased locomotor activity with involvement of an 
opioid-dependent mechanism (Leza et al., 1991). Histamine (i.c.v.) in rats had a 
biphasic action: a transient augmentation then  a reduction in locomotion (Haas et al., 
2008). Furthermore, H3R KO mice displayed reduced spontaneous locomotor 
activity (Toyota et al., 2002).   
1.6 Histamine H3R antagonists  
1.6.1 Drug Development  
Thioperamide (Figure 6) was the first potent H3R antagonist to be developed 
as a research tool to explore the function of H3Rs. However, this agent was 
associated with hepatotoxicity and the search began for more tolerable candidates 
(Schwartz, 2011).  
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Later, several compounds, like ciproxifan and clobenpropit, that share the 
basic imidazole ring with thioperamide, were developed (McLeod et al., 2003). For 
the latter imidazole-based antagonists, however, it has been shown that numerous 
metabolic interactions may develop due to the ability of the imdazaole heterocycle to 
potently inhibit CYP450 isoenzymes. Other class-related drawbacks of imidazole-
based agents include relatively poor CNS penetration and incidence of off-target 
activity at H4R or other receptors (Berlin et al., 2011, Panula et al., 2015). Therefore, 
further chemical modulation, by replacing imidazole (Figure 6) with piperidine or 
tertiary amine, resulted in the development of numerous non-imidazole H3R 
antagonists which has attracted the main focus of the H3R antagonists design work in 
recent years. Thus, the newer H3R antagonists, e.g. pitolisant, are seen as bioisosteric 
alternatives to the imidazole-based group. Extensive structure-activity relationship 
efforts in the field of drug design and development led to an understanding of the 
general structural pattern (Figure 7) consisting of the most required pharmacophores 
for a given compound to exert histamine H3R antagonistic affinity. The general 
structural pattern (Figure 7) consists of a western basic moiety, that is connected via 
an alkyl spacer to a hydrophilic (hetero-atom or -cycle) central core and an eastern 
Figure 6: Structural development of H3R antagonists by replacement of the 
disadvantageous imidazole group.     
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part that is important for H3R antagonistic affinity and is only limited by the overall 
molecular size.  
1.6.2 H3 antagonists as candidates for the treatment of epilepsy and cognitive 
disorders 
Epilepsy is a serious neurological disorder that affects around 70 million 
people worldwide from all age groups. The mortality rate is 3 times higher than the 
normal population and the risk increases with uncontrolled cases.  Pharmacological 
intervention with antiepileptic drugs (AEDs) represents the chief strategy for the 
management of this ailment. Around 60-70 % of patients respond to treatment, 
however, resistance to mono-therapy is not uncommon and drug combination is often 
inevitable (Brigo et al., 2013). Available AEDs do not bear tolerable safety profiles 
and, with poly-therapy, side effects are further augmented (Schmidt, 2002).  
Cognitive impairment accompanies some types of epilepsy at onset and 
worsens with chronic, poorly controlled seizures particularly in the developing brain 
(Elger et al., 2004). Appropriate, early management of seizures removes the insult on 
the brain cognitive function, though many AEDs themselves can negatively alter 
Figure 7: General structural pattern of non-imidazole H3R 
antagonists. Adopted from (Gemkow et al., 2009) 
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cognition (Hermann et al., 2010). Therefore, more effective, safer pharmacological 
approaches that remove seizure risk and improve the quality of life are warranted.  
Given their prominent expression and widespread distribution in the CNS, in 
addition to their regulatory function on the release of histamine as well as other 
neurotransmitters (refer to section 1.4.3), H3Rs are an attractive target for the 
treatment of several CNS diseases including epilepsy and cognitive disorders. The 
presence of different isoforms of the receptor with differential distribution in the 
brain (refer to section 1.4.3) could permit the design of selective ligands with further 
reduction of side effects. 
1.6.2.1 H3R antagonists in epilepsy  
As illustrated in Table 2, H3R antagonists attenuated or delayed convulsions 
in several electrical, chemical or genetic models of epilepsy. This effect seems to 
largely depend on H1R activation since it was reversed by CNS-penetrant H1R 
antagonists (Kakinoki et al., 1998, Zhang et al., 2003a, Sadek et al., 2014). These 
findings are supported by preclinical and clinical studies with H3R antagonists as 
discussed in section 1.5.3. Furthermore, bicuculline, a GABAA receptor antagonist, 
significantly diminished clobenpropit inhibition of amygdaloid kindling (Ishizawa et 
al., 2000). Thus an association between H3R antagonist anticonvulsive action and 
GABA transmission has been suggested.  Accordingly, two scenarios are possible, 
either 1) H3R antagonists inhibit autoreceptors and increase release of histamine that 
in turn activates H1R and consequently excites GABAergic neurons and/or 2) H3R 
antagonists directly increase GABA release through inhibition of H3R 
heteroreceptors (Figure 8).  
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In addition, clobenpropit and iodophenpropit, H3R antagonists, exert 
noncompetitive antagonism at the NR1/NR2B subunits of the NMDA receptors with 
submicromolar potency (Hansen et al., 2010). NR2 (A, B, C or D) subunits, unlike 
NR1, of NMDA receptors possess differential distribution and pharmacology (Vicini 
et al., 1998). NR2A/B subunits are expressed abnormally in dysplastic neurons of 
epileptic human cortex (Ying et al., 1999). Furthermore, selective NR1/NR2B 
NMDA antagonists like ifenprodil, have anticonvulsant activity with no cognitive 
side effects compared to non-selective NMDA antagonists (Chizh et al., 2001, Mares 
and Mikulecka, 2009). Thus a synergistic action at H3R and NMDA receptors of 
clobenopropit and iodophenpropit could explain their antiepileptic properties. Such 
observations can be utilized to create more potent dual-target agents that can be used 
for the management of epilepsy. Notably, H3R antagonists are progressing well in 
clinical trials in the field of epilepsy. Recently, pitolisant showed promising 
outcomes in proof-of-concept trials in a human photosensitivity model of epilepsy 
Figure  8: Schematic illustration of  possible mechanisms by which H3R 
antagonists affect seizures and cognition. 
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(Kasteleijn-Nolst Trenite et al., 2013). In this model, photosensitive, epileptic 
patients are exposed to intermittent flashes of light at different frequencies before 
and after test drug administration. These flashes at variable frequencies induce 
subclinical epileptiform discharges on EEG (photo-paroxysmal responses) in 
photosensitive patients. This model is an early “informative indicator” of AED’s 
effectiveness and will help in dose selection for future phase 2/3 clinical trials (Yuen 
and Sims, 2014). 
Excessive excitation of neurons can lead to excitotoxicity and neuronal death. 
Widespread neuronal necrosis can arise due to status epilepticus, prolonged or 
rapidly recurrent seizures, even at its clinically-silent, non-convulsive stage 
(Wasterlain et al., 1993). The neuronal damage that can occur during the status 
epilepticus and thereafter can impair normal brain functions including cognitive 
impairment, and potentiate further seizure activity, i.e. epileptogensis (Walker, 
2007). Therefore, early intervention to prevent seizures is the first-line of protection 
against seizure-associated neurotoxicity. Antiepileptic agents should also provide 
neuroprotection and preserve normal brain activity (Walker, 2007). In previous 
studies, the neuroprotective effects of H3R antagonists, e.g. thioperamide and ABT-
239, have been revealed in in vitro and in vivo kainic acid- or 3-nitropropionic acid 
(3-NP)-induced neurotoxicity models (Kukko-Lukjanov et al., 2006, Bhowmik et al., 
2014). It has been observed that H3R up regulation and H1R down-regulation 
coincided with excessive neuronal damage and behavioral effects as a consequence 
of 3-NP-induced neurotoxicity in hamster and rat (Canonaco et al., 2005). Moreover, 
the H3R antagonist clobenopropit prevented NMDA-induced neurotoxicity of 
cultured cortical neurons by increasing GABA release mediated by cAMP/PKA (Dai 
et al., 2007a). Furthermore, a previous study showed that the H3R antagonist ABT-
26 
 
239 protected against seizures and neuronal damage induced by kainic acid through 
augmentation of PKA/CREB and Akt/GSK3βser9 signaling pathways  that regulate 
neuronal survival and inhibit excitotoxicity. Interestingly, these signaling pathways 
are also involved in learning, memory and neuronal plasticity. In summary, H3R 
antagonists have advantages over other available AEDs of possessing disease 
modifying properties and may ameliorate cognitive decline that is associated with 
epilepsy especially in the developing brain (Elger et al., 2004). Indeed, thioperamide 
and JNJ-5207852 prevented different memory deficits induced by PTZ kindling in 
weanling mice (Jia et al., 2006). Notably, H3R antagonists have cognitive enhancing 
properties in other models as reviewed below. 
1.6.2.2 H3R antagonists in cognition 
Many H3R antagonists have been shown to facilitate learning and memory as 
shown in Table 1. First possible etiology stems from their wake-promoting properties 
in preclinical and clinical studies (Parmentier et al., 2007, Lin et al., 2011, 
Dauvilliers et al., 2013). The arousal effect is combined with enhanced cortical fast 
rhythms that are correlated with higher brain functions including alertness, attention 
and cognition (Parmentier et al., 2007, Lin et al., 2011). Secondly, H3R antagonists 
increase the synthesis and release of histamine and its associated memory 
enhancement (Table 1). In addition, H3R antagonists can increase the release of 
other neurotransmitters involved in cognition. Moreover, H3R antagonists increase 
acetylcholine release in the prefrontal cortex, anterior cingulate cortex and 
hippocampus (Mochizuki et al., 1994, Fox et al., 2005, Medhurst et al., 2007), 
dopamine release in the prefrontal cortex and the anterior cingulated cortex (Fox et 
al., 2005, Medhurst et al., 2007), and norephinephrine in the anterior cingulate cortex 
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(Medhurst et al., 2007).  The mechanism by which H3R antagonists influence other 
neurotransmitter release is complex. It involves 1) excitation of the neurotransmitter 
neuron through H1/H2, 2) excitation or inhibition of a “third-party” excitatory or 
inhibitory neuron that in turn modulates neurotransmitter release and 3) direct 
increase of the neurotransmitter release through inhibition of H3R heteroreceptors 
(Figure 8 above). 
Several H3R antagonists have entered phase 2 clinical trials to evaluate their 
effectives against cognitive deficits associated with Schizophrenia, AD, and ADHD. 
Two separate studies with the H3R antagonist GSK239512 have indicated its 
beneficial effects in attention and memory in patients with mild-moderate AD 
(Nathan et al., 2013, Grove et al., 2014). However, further larger scale testing is 
required to clarify its effectiveness (Nathan et al., 2013). Interestingly, an essential 
component or prerequisite of cognition is arousal and vigilance, both of which are 
modulated by H3R neurotransmission. Wake-promoting effects have been 
demonstrated with the H3R antagonists pitolisant (Inocente et al., 2012) and MK-
7288 (Sun et al., 2013). In addition, enhancement of cortical fast rhythms on EEG 
has been observed with pitolisant (Kasteleijn-Nolst Trenite et al., 2013).  
Supported by the evidence discussed above, the current study aimed to 
investigate the activity of newly developed H3R antagonists (1-12) in several in vivo 
epilepsy models, including MES-, PTZ- and strychnine (STR)-induced seizures. In 
addition, selected H3R antagonist in terms of seizure control was nominated for 
further cognitive in vivo tests in naïve animals utilizing PAT. The newly synthesized 
H3R antagonists (1-12) belong to the non-imidazole class of compounds and possess 
in vitro antagonistic binding properties in the nanomolar range at the human 
histamine H3R.  
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Chapter 2: Aims and Objectives 
 
Previous studies have revealed the anticonvulsant and procognitive effects of 
the imidazole-based H3R antagonists. Since the effects of non-imidzole based H3R 
antagonists on memory and seizures in the same species are still unknown. Our main 
aim was to investigate the effects of newly synthesized non-imidazole H3R 
antagonists (1-12) of high in vitro antagonist affinities for hH3Rs, on their in vivo 
anticonvulsant in MES-, (PTZ)-, and (STR)-induced seizures and procognirtive 
effects in passive avoidance paradigm in male adult rats. The novel non-imidazole 
H3R antagonists (1-12) were synthesized based on structure-activity relationship 
studies of pitolisant and related derivatives and incorporated different alkyl spacers 
(3, 5, or 6 methylene groups) and various aromatic substitutions (see Material & 
Methods section).The detailed objectives of the experiments are as follows: 
A. Investigate anticonvulsant effects of H3R antagonists 1-12 on MES-, 
(PTZ)-, and (STR)-induced seizure models. 
 B. Dose-dependency of anticonvulsant effects provided by a selected H3R 
antagonist in  in terms of seizure control in MES, (PTZ), and/or (STR) seizure 
models 
C. Abrogation study of anticonvlusant effects provided by the selected H3R 
antagonist in MES-, (PTZ)-, and/or (STR)-induced seizure models. 
D. Memory-enhancing effects of a selected H3R antagonist offering the 
greatest, histamine-dependent seizure control on acquisition, consolidation, and 
retrieval stages in an inhibitory avoidance paradigm. 
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E. Abrogation study of memory-enhancing effect provided by most effective 
H3R antagonist on the level of acquisition, consolidation, and/or retrieval in an 
inhibitory avoidance paradigm.  
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Chapter 3: Materials and Methods 
 
3.1 Animals 
Male Wistar rats 180-200 g, bred at the Central Animal Facility of the UAE 
University, were used. In the study, animals were maintained in an air-conditioned 
room with controlled temperature (24±2 C) and humidity (55±15%) under a 12-h 
light/dark cycle (lights on at 07:00 h). The animals were given free access to food 
and water. Experiments were conducted between 9:00 and 15:00 h, and all 
procedures were performed in accordance with the guidelines of the European 
Communities Council Directive of 24 November 1986 (86/609/EEC) and were 
approved by the Institutional Animal Ethics Committee of the College of Medicine 
and Health Sciences, United Arab Emirates University (A9-14) for epilepsy and 
(A30-13) for precognitive study. 
3.2 Drugs 
Phenytoin (PHT), valproic acid (VPA), R-(α)-methyl-histamine (RAMH), the 
brain-accessible H1R antagonist pyrilamine (PYR) and H2R antagonist zolantidine 
(ZOL), donepezil hydrochloride (DOZ), pentylenetetrazole (PTZ), and strychnine 
(STR) were purchased from Sigma-Aldrich (St Louis, Missouri, USA). The test 
compounds 1 and 2 were synthesized at the Institute of Pharmaceutical and 
Medicinal Chemistry, Heinrich Heine University, Düsseldorf, Germany. The 
standard H3R antagonist pitolisant (PIT) and the test compounds, namely the H3R 
antagonists (3-12) were synthesized in the Department of Technology and 
Biotechnology of Drugs, Kraków/Poland as described previously (Lazewska et al., 
2006) (Figure 9). The test compounds were dissolved in either 0.9% saline or 
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isotonic 10% DMSO and administered intraperitoneally (i.p.) at a volume of 1 ml/kg. 
Doses of test compounds 1-12 as well as reference compounds were expressed in 
terms of the free base. 
3.3 In vivo models of seizures  
3.3.1 Maximal electric shock  
MES is a model of generalized tonic-clonic seizures arising from the brain 
stem on exposure to auricular stimulation. Through ear electrodes, an alternating 
current with 50 Hz frequency and 120 mA intensity for 1-sec was applied to each rat. 
Duration of tonic hind limb extension (THLE), tonic phase, was taken as a measure 
Figure  9: Chemical structures of compounds used in this study. 
a
Compounds were 
purchased from Sigma-Aldrich (St Louis, Missouri, USA). 
b
H3R antagonists were 
synthesized in
 
the Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine 
University, Düsseldorf, Germany. 
c
H3R antagonists were synthesized in the Department 
of Technology and Biotechnology of Drugs, Kraków, Poland. 
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of seizures. Reduction in duration or complete absence of THLE was regarded or 
defined as protection from seizures. 
Animals were divided into different groups (a saline treated group and groups 
receiving test compounds) each containing 7-8 rats. Saline, PHT 10 mg/kg (a 
standard antiepileptic drug), PIT 10 mg/kg (a standard H3R antagonist), and test 
compounds (1-12) each at dose of 10 mg/kg were injected i.p. 30 minutes before 
shock application. H3R test compounds with significant protection against THLE 
were then tested at other doses (5 and 15 mg/kg, i.p.) applying the same protocol to 
explore dose dependency of the protective effect provided by the respective test 
compound. In further experiments, rats were injected with the selected H3R 
antagonist (test compound) offering the highest protection in combination with CNS-
penetrant HR1 antagonist (PYR, 10 mg/kg, i.p.) to clarify the mechanism of seizure 
protection. 
3.3.2 Chemically induced seizures 
PTZ, a GABAA antagonist, and STR, a glycine receptor antagonist, were the 
two proconvulsant compounds used in the current study. Immediately after i.p. 
administration of PTZ 60 mg/kg or STR 3.5 mg/kg (Loscher, 2011, Sowemimo et al., 
2011, Branco Cdos et al., 2013, Lopes et al., 2013), seizure activity was recorded for 
30 minutes. Graded scores (0-5) were utilized to evaluate the resulting behavioral 
phenomena (seizures) as the following: 0 = no seizures, 1 = eye or facial twitches, 2 
= convulsive waves across the body, 3 = myo-clonic jerks or rearing, 4 = turn over 
onto one side position, and 5 = turn over onto back position, generalized tonic-clonic 
seizures, or die during the experiment period. Maximum seizure scores were 
evaluated at 10-min intervals (10 min, 20 min and 30 min). Significant reduction of 
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the maximum score at each time interval was regarded or defined as protection from 
seizures at that interval. 
Animals were divided into groups of 6-8 rats each according to the test 
compounds. Saline, VPA 100 mg/Kg (in PTZ-induced seizure model), VPA 300 
mg/kg (in STR-induced seizure model), PIT 10 mg/kg and test compounds (1-12) 
each at 10 mg/kg were injected i.p. 30 min. before the administration of either PTZ 
or STR. Test compounds that showed beneficial anti-seizure activity as defined 
above were further tested at other doses ( 5 and 15 mg/kg, i.p.) against PTZ or STR-
induced seizures to explore the dose dependency of their protective effect. In a 
further experiment, the test compounds with the highest protection were co-injected 
with PYR (10 mg/kg, i.p.) to clarify the mechanism of their anti-seizure effect in the 
respective model (PTZ- or STR-induced seizure model). 
3.4 Behavioral tests 
3.4.1 Open Field Test 
The open field test is a prerequisite for memory studies that require animal 
movement and normal anxiety level. Any effect of compounds on the locomotor 
activity or anxiety of animals could alter or confound their activity in the memory 
test. Locomotor activity and anxiety levels were examined in an open field test 
(OFT). A rectangular 112x56x56 cm
3
 (length/width/height) box that is open from 
above provides the testing arena (Figure 10). The floor of the box was divided into 
32 equal squares (14 cm in diameter). The 4 central squares were regarded as the 
“center” of the field. At the beginning of the test, animals were transferred to the 
arena only by their tails and placed in the center where they are allowed to move 
freely for 3 minutes. During this time animal activity was recorded by a digital 
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camera placed above the arena. Video recordings were utilized for assessment. When 
a rat moved from one square to another with its four paws, one line crossing was 
noted and a distance of 14 cm is recorded. The following parameters were manually 
scored: the number of lines crossed and time spent in the center of the arena during a 
3-minute test (Charlier et al., 2013). More time spent in the peripheral area was 
usually taken as a measure of a higher level of anxiety and vice versa. After each 
test, the arena was sprayed with 70% ethanol and wiped thoroughly to remove any 
residual odor. Animals were divided into groups of 7 rats each. 30 minutes prior to 
the test, animals were injected i.p. with saline, PIT 10 mg/kg, DOZ 1 mg/kg or H3R 
test compound 4 at various doses (2.5, 5 and 10 mg/kg, i.p.). Doses of H3R 
antagonist 4 that didn’t significantly alter locomotor or anxiety levels were used for 
subsequent memory tests. 
3.4.2 Passive Avoidance Test (step-through) 
The test was performed in a Passive Avoidance Apparatus (Step-through 
Cage,  7550, Ugo Basile, Comerio, Italy). The  apparatus consisted of two equal size 
Figure  10: Open field arena utilized to explore locomotion and anxiety levels. 
(A) Central area surrounded by a red square, when an animal stays in the center 
it means low level of anxiety and vice versa. (B) No locomotion, animal is not 
crossing any line or staying within a square. (C) Animal is about to cross a line, 
i.e.14 cm distance is recorded. 
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compartments (51 x 25 x 24 cm each) with grid floors which can be electrified 
separately. The walls of the first compartment are painted white, and the second 
compartment is dark with walls painted black. An automated guillotine door 
separates the two compartments (Figure 11).  
PAT is a long-term memory test. It consists of two types of session, namely a 
training session and a test session separated usually by a 24 hour interval. This test 
exploits the fact that rodents prefer a dark environment. Each rat was introduced to 
the white compartment for 30 seconds to explore then the door separating the dark 
chamber was automatically opened. Within a minute or less, rats should move to the 
dark or otherwise would be excluded from the study. When animals reached the dark 
compartment with all four paws, the door was closed within 3 seconds and an 
inescapable foot shock (intensity = 0.5 mA, duration= 3 seconds) was administered. 
This concluded the training session and 70 % ethanol was used to clean the 
compartments to remove olfactory cues after each experiment. In the same manner 
and 24 hr later the animals were again placed in the white compartment and 300 
seconds as a cut-off time was provided while the door was open. Once the rats 
moved to the dark compartment, the test was ended without any foot shock to be 
Figure  11: Passive avoidance test apparatus utilized in this study. 
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delivered. The latency to move to the dark compartment (step-through latency) was 
utilized to evaluate the memory of the animals. Higher latency indicated better recall. 
To investigate the effect of test compound 4 on several components of 
memory formation, H3R antagonist 4 was injected in separate groups of animals at 
different time points (Figure 12). Drugs were given 30 minutes before the training 
session (time point 1), directly after the training (time point 2) or 30 minutes before 
the test session (time point 3). These three separate experiments were employed to 
explore their activity in memory acquisition, consolidation or retrieval, respectively.  
To reduce the number of animals and even out experience of injection among all 
animals, all the groups received saline injection at all three time points, except when 
Figure  12: Schematic description of passive avoidance test protocol and time 
points of injections to test effect of a compound in several aspects of memory:  
acquisition, consolidation and retrieval. 
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the compound was given, (Figure 12) and one control group (only saline treated at all 
time points) was used for comparison. 
Any memory-improving effect of  the selected H3R antagonist 4 was then 
further investigated by abrogation studies that included co-administration of the most 
effective dose of H3R antagonist 4  and zolantidine (ZOL, 10 mg/kg, i.p.) or 
pyrilamine (PYR, 10 mg/kg, i.p.). Doses of ZOL and PYR were selected according 
to previous studies (Orsetti et al., 2001, Sadek et al., 2013, Sadek et al., 2014). 
3.5 Statistical analysis              
  
For statistical comparisons, the software package SPSS 20.0 (IBM Middle 
East, Dubai, UAE) was used. All data were expressed as the means ± SEM. All the 
results were analyzed using one-way ANOVA analysis of variance (ANOVA) with 
Treatment (vehicle or test compound) and Dose (test compound) as the between-
subjects factor. In case of a significant effect, post hoc comparisons were performed 
with Bonferroni's test. The criterion for statistical significance was set at a P value of 
less than 0.05. 
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Chapter 4: Results 
 
4.1 Effect of H3R antagonists 1-12 on MES-induced seizures 
Figure 13 shows the protective effects of acute systemic administration of test 
compounds 1-12 on MES-induced seizures in rats. One-way analysis of variance 
showed that treatment with PHT, PIT, and H3R ligands 1-12 (10 mg/kg, i.p.) exerted 
a significant protective effect against MES-induced convulsions [F(14,90) = 34.422; 
P<0.05]. Among the compounds tested 4, 8, 10, 11, and 12 provided the best 
protection against MES-induced convulsion in rats pretreated with 10 mg/kg, i.p. 
when compared with the saline-treated group [F(1,12) = 235.86, 16.52, 53.04, 25.99, 
Figure 13: Protective effect of an intraperitoneal injection of H3R antagonists 1-12 on 
maximal electroshock-induced seizure. The figure shows the protective effects of 
phenytoin (PHT, 10 mg/kg, i.p.), pitolisant (PIT, 10 mg/kg, i.p.), and H3R antagonists 
1–12 (10 mg/kg, i.p.) on the duration of tonic hind limb extension (THLE) induced in 
the maximal electroshock (MES) model in rats. Data are expressed as mean ± SEM 
(n=7). 
*
P<0.05 vs. the saline-treated group. 
**
P<0.001 vs. saline-treated, group. 
#
P<0.001 vs. PIT (10 mg)-treated group. 
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77.37, and 11.66, respectively, P< 0.05]. When compared with the group pretreated 
with PIT (10 mg/kg, i.p.), only H3R antagonist 4 showed significantly higher 
protective effect on MES-induced seizures [F(1,12) = 41.65, P<0.05]. Also, the 
protective effect observed for H3R antagonist 4 (10 mg/kg, i.p.) was comparable to 
those observed with PHT-treated group [F(1,12) = 1.66, p=0.22, NS]. 
4.2 H3R antagonist 4 dose-dependently reduced MES-induced seizures 
Figure 14 shows the protective and dose-dependent effects of acute 
administration of H3R antagonist 4 (5, 10 or 15 mg/kg, i.p.) on MES-induced 
seizures in rats. One-way analysis of variance showed that pretreatment with PHT 
(10 mg/kg, i.p.), PIT (10 mg/kg, i.p.), and 4 (5, 10, and 15 m/kg, i.p.) exerted 
significant protective effects against MES-induced convulsions [F(5,36) = 83.05; P < 
0.05]. Moreover, significant increases in protective effects were observed after 
pretreatment with 10 and 15 mg/kg of 4 when compared with 5 mg/kg of the same 
compound [F(1,12) = 74.59 and F(1,12) = 92.86; P < 0.05], respectively. 
Also, the protection observed for H3R antagonist 4 (5, 10 and 15 m/kg, i.p.) 
was significant when compared with the saline-treated group [F(1,12) = 31.35, F(1,12) = 
235.87, and F(1,12) = 257.19, respectively, P < 0.05]. The results, also, show that H3R 
antagonist 4 exhibited the highest protection against MES-induced convulsion in rats 
pretreated with 10 and 15 mg/kg, i.p. and were similar to the protective effects 
observed for the standard AED PHT (10 mg/kg, i.p.) [F(1,12) = 1.66, and F(1,12) = 1.96, 
respectively, all P < 0.05]. 
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4.3 H3R antagonist 4-induced shortening of THLE duration was abrogated by 
PYR and RAMH in MES-induced seizures 
Figure 15 shows reversal of the protective effects of H3R antagonist 4 by 
pretreatment with 10 mg/kg of the CNS penetrant histamine H1R antagonist 
pyrilamine (PYR) 30 min, and with 10 mg/kg of RAMH 15 min before MES 
challenge with [F(1,12) = 12.38, for the comparison between 4 + PYR and 4 alone], 
and [F(1,12) = 66.67, for the comparison between 4 + RAMH and 4 alone].  
 
 
 
 
Figure 14: Dose-dependent protective effects of H3R antagonist 4 against maximal 
electroshock (MES)-induced seizures. The figure shows the protective effects of 
phenytoin (PHT, 10 mg/kg, i.p.), pitolisant (PIT, 10 mg/kg, i.p.), and H3R antagonist 4 
(5, 10, 15 mg/kg, i.p.) on the duration of tonic hind limb extension (THLE) induced in 
MES model in rats. Data are expressed as mean ± SEM (n=7). 
*
P < 0.001 vs. the saline-
treated group. 
#
P < 0.001 vs. 5 mg H3R antagonist 4. 
&
P < 0.001vs. PIT-treated group. 
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4.4 Effect of H3R antagonists 1-12 on PTZ-induced seizures 
Figure 16 shows the effects of H3R ligands 1-12 (10 mg/kg, i.p.) and the 
standard H3R antagonist PIT in comparison to the protective effects of the reference 
antiepileptic drug VPA in PTZ-induced seizures in rats. In PTZ-induce seizure, H3R 
ligands 5, 6, and 12 provided significant protective effects relative to the saline-
treated group after 10, 20, and 30 min of observation [P < 0.05]. Among the most 
effective compounds, only H3R ligand 6 provided full protection when compared 
with saline-treated group after 10, 20, and 30 with [F(1,12) = 101.4; P < 0.05], [F(1,12) 
= 44.74; P < 0.05], and [F(1,12) = 16.8; P < 0.05], respectively. However, H3R ligand 
4 (10 mg/kg, i.p.) did not provide significant protective effect relative to the saline-
treated after 10, 20, and 30 min [F(1,12) = 0.10, 3.68, and 0.021, respectively, all NS]. 
Similarly, PIT failed to provide protection in the PTZ-induced seizure model after 
Figure 15: Effect of PYR and RAMH pretreatment on the protection by H3R 
antagonist 4 on maximal electroshock (MES)-induced convulsions in rats. Saline, 
H3R antagonist 4 (10 mg/kg), H3R antagonist 4 (10 mg/kg) + PYR (10 mg/kg), 
saline + PYR (10 mg/kg), H3R antagonist 4 (10 mg/kg) + RAMH (10 mg/kg, and 
saline + RAMH (10 mg/kg) were injected 30 min before electroshock. Effects shown 
are expressed as the duration of tonic hind limb extension (THLE) induced in the 
MES model in rats. Data are expressed as mean ± SEM (n= 7). 
*
P < 0.001vs. the 
saline-treated group. 
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10, 20, and 30 min [F(1,12) = 0.03, 0.01, and 0.50, respectively, all NS]. However, 
VPA (VPA 100 mg/kg) provided significant protection when compared with saline-
treated group after 10, 20, and 30 min with [F(1,12) = 101.4; P < 0.005], [F(1,12) = 
44.74; P < 0.05], and [F(1,12) = 16.8; P < 0.05], respectively.  
4.5 Dose-dependent effects of H3R antagonist 6 on PTZ-induced seizures 
Figure 17 shows the protective and dose-dependent effects of acute 
administration of H3R ligand 6 (5, 10 or 15 mg/kg, i.p.) on PTZ-induced seizures in 
rats. One-way analysis of variance showed that pretreatment with reference 
antiepileptic drug VPA and H3R ligand 6 (5, 10, and 15 m/kg, i.p.) exerted a 
significant protective effect against PTZ-induced convulsions with [F(3,24) = 53.55; P 
< 0.05], [F(3,24) = 24.13; P < 0.05], and [F(3,24) = 10.50; P < 0.05] for 10, 20, and 30 
Figure 16: Protective effect of pretreatment with H3R antagonists 1-12 on 
pentylenetetrazole (PTZ)-induced seizures in rats. Valproic acid (VPA, 100 mg/kg, i.p.) 
as a reference AED in PTZ-induced seizure (Serdiuk and Gmiro, 2014), 10 mg of 
pitolisant (PIT), and 10 mg of the respective H3R antagonist were injected i.p. 30 min 
before PTZ (60 mg/kg, i.p.) treatments. Effects shown are expressed as score of seizures 
after 10 min, 20 min and 30 min of PTZ injection. Data are expressed as the mean ± 
SEM (n=7). *P<0.05 vs. the saline-treated group.
&
Full protection for VPA (100 mg/kg, 
i.p.), H3R antagonists 5 (after 30 min), 6 (after 10, 20, and 30 min), and 12 (after 30 
min). 
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min observation, respectively. The results showed that significant and full protective 
effect was provided at 10, 20, and 30 min after pretreatment with 10 and 15 mg/kg of 
H3R antagonist 6. Comparable full protection was observed with 5 mg/kg of H3R 
antagonist 6 only at 30 min [F(1,12) = 14.00; P < 0.05 for 30 min] , yet significant 
protective effect of lesser magnitude was recorded at 10 and 20 min [P < 0.05 for 10 
and 20 min]. 
 
 
 
 
4.6 H3R antagonist 6-provided protection was partially abrogated by PYR in 
PTZ-induced seizures 
Figure 18 shows the protective effect of H3R ligand 6 when co-administered 
with 10 mg/kg of the CNS penetrant histamine H1R antagonist pyrilamine (PYR) 30 
min before PTZ challenge [F(1,12) = 37.75 (P < 0.05) and 6.50 (P < 0.05) for the 
Figure 17: Dose-dependent protective effects of H3R antagonist 6 against 
pentelenetetrazole (PTZ)-induced seizures. The figure shows the protective effects 
of Valproic acid (VPA, 100 mg/kg, i.p.) as a reference AED and H3R antagonist 6 
(5, 10, 15 mg/kg, i.p.) on the score of PTZ-induced seizure model in rats. Effects 
shown are expressed as score of seizures after 10 min, 20 min and 30 min of PTZ 
injection. Data are expressed as mean ± SEM (n=7). 
*
P < 0.001 vs. the saline-treated 
group. 
&
Full protection. 
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comparison between H3R ligand 6 + PYR and H3R ligand 6 alone for 10 min and 20 
min  of  observation,  respectively;  all P < 0.05].  However,  and only  after 30  min  
of observation , the protective effect of H3R ligand 6 was reversed by pretreatment 
with pyrilamine (PYR) [F(1,12) = 0.08; P=0.78 for the comparison between H3R 
ligand 6 + PYR and H3R ligand 6 alone for 30 min of observation].  
4.7 Effect of H3R antagonists 1-12 on STR-induced seizures  
Figure 19 shows the effects of H3R ligands 1-12 (10 mg/kg, i.p.) and the 
standard H3R antagonist PIT in comparison to the protective effects of reference 
antiepileptic drug VPA in STR-induced seizures in rats. In STR-induced seizure, 
H3R ligands 8 and 11 provided significant protective effects relative to the saline-
Figure 18: Effect of PYR pretreatment on the protection by H3R antagonist 6 against 
pentelenetetrazole (PTZ)-induced seizures in rats. Saline, H3R antagonist 6 alone, 
H3R antagonist 6 (10 mg/kg) + PYR (10 mg/kg) or saline + PYR (10 mg/kg) were 
administered 30 min before PTZ injection. Effects shown are expressed as score of 
seizures after 10 min, 20 min and 30 min of PTZ injection. Data are expressed as 
mean ± SEM (n=7). 
*
P < 0.05 for seizure scores vs. the saline-treated group.
 &
Full 
protection. 
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treated group after 10, 20, and 30 min of observation [P < 0.05]. The results showed 
that H3R ligand 8 provided significant protection when compared with saline-treated 
group after 10, 20, and 30 with [F(1,12) = 24.08; P < 0.05], [F(1,12) = 40.33; P < 0.05], 
and [F(1,12) = 20.74; P < 0.05], respectively.  
Also, H3R antagonist 11 (10 mg/kg, i.p.) provided significant protective 
effect relative to the saline-treated after 10, 20, and 30 min of observation [F(1,12) = 
12.10; P < 0.05, F(1,12) = 5.113; P < 0.05, F(1,12) = 19.09; P < 0.05, respectively. 
Moreover, the standard H3R ligand PIT (10 mg/kg, i.p.) failed to provide protection 
in STR-induced seizure model after 10, 20, and 30 min [F(1,12) = 0, 3.32, and 3.50; all 
NS], respectively. However, VPA (VPA 300 mg/kg, i.p.) provided significant 
protection when compared with saline-treated group after 10, 20, and 30 with [F(1,12) 
= 41.82; P < 0.05], [F(1,12) = 144.15; P < 0.05], and [F(1,12) = 81.82; P < 0.05], 
respectively. 
Figure 19: Protective effect of pretreatment with H3R antagonists 1-12 on strychinine 
(STR)-induced seizures in rats. Valproic acid (VPA, 300 mg/kg, i.p.) as a reference AED 
in STR-induced seizure (Serdiuk et al., 2014), 10 mg of pitolisant (PIT), and 10 mg of 
the respective H3R antagonist 1-12 were injected i.p. 30 min before STR (3.5 mg/kg, 
i.p.) treatments. Effects shown are expressed as score of seizures after 10 min, 20 min 
and 30 min of STR injection. Data are expressed as the mean ± SEM (n=7). 
*
P<0.05 vs. 
the saline treated group. 
&
Full protection. 
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4.8 Effects of H3R antagonist 4 on acquisition 
Figure 20 shows no significant effects of H3R antagonist 4 (5 and 10 mg/kg, 
i.p.), PIT (10 mg/kg, i.p.), and DOZ (1 mg/kg, i.p.) on memory acquisition in the one 
trial inhibitory avoidance task [F(5,40) = 1.75; P=0.14]. However, only rats pretreated 
in the pre-training session with H3R antagonist 4 (2.5 mg/kg, i.p.) showed a 
significant effect on step-through latencies when compared with the saline-treated 
with [F(1,12) = 12.09; P < 0.05]. Surprisingly, higher doses of H3R ligand 4 (5 and 10 
mg/kg, i.p.), PIT (10 mg/kg, i.p.), and DOZ (1 mg/kg, i.p.) failed to improve 
performance of rats treated in the pretraining session with [F(1,13) = 4.26, F(1,13) = 
0.04, F(1,12) = 3.46, and F(1,14) = 3.87; all NS], respectively. 
 
 
Figure 20: Effect of pre-training administration of H3R antagonist 4 on acquisition in 
an inhibitory avoidance conditioned response in adult male rats. Gray columns 
represent the mean step-through latencies measured during the retention test (test 
latencies) and black columns the mean step-through latencies measured during the 
training trial before the delivery of the foot-shock (pre-shock latencies). Rats were 
injected with H3R antagonist 4 (2.5, 5 or 10 mg/kg, i.p.), PIT (10 mg/kg, i.p.), or 
donepezil (DOZ, 1 mg/kg, i.p.) 30 min before the training session. Memory retention 
was measured 24 h after training. 
*
P < 0.005 for mean step-through latencies vs. the 
value of the saline group. Data are expressed as mean ± SEM (n=7). 
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4.9 Effect of PYR and ZOL on the H3R antagonist 4-provided memory 
improvement of acquisition in an inhibitory avoidance conditioned response 
Figure 21 shows the results of the experiment testing whether the H3R 
antagonist 4 (2.5 mg/kg)-induced improvement of acquisition was mediated through 
histaminergic neurotransmission. For this purpose, a group of rats (n=7 for each 
group) was injected with Saline + 4 (2.5 mg/kg), Saline + 4 (2.5 mg/kg) + PYR (10 
mg/kg), or 4 (2.5 mg/kg) + ZOL (10 mg/kg) 30 min before the test session. As 
depicted in Figure 21, one-way ANOVA repeated measure with Treatment as the 
between-subject factor indicated a significant effect of this factor on latency time 
[F(5,36) = 5.13; P < 0.05). Pairwise comparisons reported that acute systemic injection 
of 4 (10 mg/kg) improved STL time when compared to the (Saline)-treated group 
[F(1,12) = 9.90; P < 0.05]. This 4-induced improvement of latency time was not 
Figure 21: Effect of PYR and ZOL on acquisition improvement of H3R antagonist 4 
in an inhibitory avoidance conditioned response in rats. Gray columns represent the 
mean STLs measured during the retention test (test latencies) and black columns the 
mean STLs measured during the training trial before the delivery of the foot-shock 
(pre-shock latencies). Rats were injected with Saline + 4 (2.5 mg/kg), 4 (2.5 mg/kg) 
+ PYR (10 mg/kg), 4 (2.5 mg/kg) + ZOL (10 mg/kg), Saline + PYR (10 mg/kg), or 
Saline + ZOL (10 mg/kg) 30 min before the test session. 
*
P < 0.05 for mean STLs vs. 
the value of the (Saline)-treated group. Data are expressed as mean ± SEM (n=7). 
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reversed following ZOL (10 mg/kg) injection [F(1,12) = 0.04; p=0.84: Saline + 4 vs. 4 
+ ZOL]. Also, systemic injection of PYR (10 mg/kg) failed to reverse the 4-induced 
improvement of latency time  when  compared  to the 4 (10 mg/kg)-treated  group  
with [F(1,12) = 1.08; P=0.32]. Also, neither Saline + Saline vs. PYR + Saline, nor 
Saline + Saline vs. ZOL + Saline differences were significant (p=0.77 and p=0.76, 
respectively). 
4.10 Effects of H3R antagonist 4 on consolidation 
Figure 22 shows the effects of H3R antagonist 4 (2.5, 5, and 10 mg/kg, i.p.), 
PIT (10 mg/kg, i.p.), and DOZ (1 mg/kg, i.p.) on memory consolidation in the one-
trial inhibitory avoidance task. One-way analysis of variance showed that treatment 
Figure  22: Effect of post-training administration of H3R antagonist 4 on 
consolidation in an inhibitory avoidance conditioned response in male adult rats. 
Gray columns represent the mean step-through latencies measured during the 
retention test (test latencies) and black columns the mean step-through latencies 
measured during the training trial before the delivery of the foot-shock (pre-shock 
latencies). Rats were injected with 4 (2.5, 5 or 10 mg/kg, i.p.), PIT (10 mg/kg, i.p.), 
or donepezil (DOZ, 1 mg/kg, i.p.) immediately after the training trial. Memory 
retention was measured 24 h after training. Data are expressed as mean ± SEM 
(n=7). 
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with PIT (10 mg/kg, i.p.), DOZ (1 mg/kg, i.p.), and H3R antagonist 4 (2.5, 5, and 10 
mg/kg, i.p.) injected immediately after the training session, did not enhance the 
effects on step-through latencies [F(5,41) = 0.50; P=0.78] measured 24 h later. Among 
the compounds tested, rats  pretreated  with  4  (2.5, 5, and  10 mg/kg, i.p.),  PIT  (10 
mg/kg, i.p.),  and  DOZ (1 mg/kg, i. p.) showed no significant effect on mean step-
through latencies when compared with the saline-treated group with [F(1,13) = 2.51, 
F(1,13) = 0.43, and F(1,13) = 0.57, F(1,14) = 2.54, and F(1,12) = 2.57; all NS], respectively. 
4.11 Effects of H3R antagonist 4 on retrieval 
 Figure 23 displays the effects of H3R ligand 4 (2.5, 5, and 10 mg/kg, i.p.), 
PIT (10 mg/kg, i.p.), and DOZ (1 mg/kg, i.p.) on the retrieval process. One-way 
analysis of variance showed that treatment 4 (5 and 10 mg/kg, i.p.) and DOZ (1 
mg/kg, i.p.) injected before the retention test exerted a significant effect on step-
through latencies with [F(1,12) = 5.11, F(1,12) = 9.08, and F(1,15) = 2.59; all P < 0.05], 
respectively. However, the step-through latencies of rats injected with 4 (2.5 mg/kg, 
i.p.), and 10 mg/kg PIT were not significantly different from saline-treated with 
[F(1,12) = 3.46; p=0.09] and [F(1,14) = 0.19; p=0.67], respectively, all NS. 
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4.12 Effect of PYR and ZOL on the H3R antagonist 4-provided memory 
improvement of retrieval in an inhibitory avoidance conditioned response 
Figure 24 shows the results of the experiment in which it was tested whether 
the H3R antagonist 4 (10 mg/kg)-induced improvement of retrieval was mediated 
through histaminergic neurotransmission. For this purpose, a group of rats (n=7 for 
each group) was injected with Saline + 4 (10 mg/kg), with Saline + 4 (10 mg/kg) + 
PYR (10 mg/kg), or with 4 ( 10 mg/kg) + ZOL (10 mg/kg) 30 min before the test 
session.  
As depicted in Figure 24, one-way ANOVA repeated measure with treatment 
as the  between-subject factor indicated  a significant effect of this factor  indicated a 
Figure 23: Effect of pre-retrieval administration of H3R antagonist 4 on retrieval in an 
inhibitory avoidance conditioned response in male adult rats. Gray columns represent 
the mean step-through latencies measured during the retention test (test latencies) and 
black columns the mean step-through latencies measured during the training trial 
before the delivery of the foot-shock (pre-shock latencies). Rats were injected with 4 
(2.5, 5 or 10 mg/kg, i.p.), PIT (10 mg/kg, i.p.), or donepezil (DOZ, 1 mg/kg, i.p.) 30 
min before the retention test. 
*
P < 0.05 for mean step-through latencies vs. the value of 
the saline group. Data are expressed as mean ± SEM (n=7). 
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significant effect of this factor on latency time [F(5,36) = 4.42; P < 0.05). Pairwise 
comparisons reported that acute systemic injection of 4 (10 mg/kg) improved STL 
time when compared to the (Saline)-treated group [F(1,12) = 7.86; P < 0.05]. This 4-
induced improvement of latency time was reversed following ZOL (10 mg/kg) 
injection [F(1,12) = 0.02; p=0.88: Saline + Saline vs. 4 + ZOL]. However, systemic 
injection of PYR (10 mg/kg) failed to reverse the 4-induced improvement of latency 
time when compared to the 4 (10 mg/kg)-treated group with [F(1,12) = 0.19; p=0.67]. 
Also, neither Saline + Saline vs. PYR + Saline, nor Saline + Saline vs. ZOL + Saline 
differences were significant (p=0.85 and p=0.80, respectively). 
Figure  24: Effect of PYR and ZOL on retrieval improvement of H3R antagonist 4 in 
an inhibitory avoidance conditioned response in rats. Gray columns represent the 
mean STLs measured during the retention test (test latencies) and black columns the 
mean STLs measured during the training trial before the delivery of the foot-shock 
(pre-shock latencies). Rats were injected with Saline + 4 (10 mg/kg), 4 (10 mg/kg) + 
PYR (10 mg/kg), 4 (10 mg/kg) + ZOL (10 mg/kg), Saline + PYR (10 mg/kg), or 
Saline + ZOL (10 mg/kg) 30 min before the test session. 
*
P < 0.05 for mean STLs 
vs. the value of the (Saline)-treated group. 
#
P < 0.05 for mean STLs of 4 (10 mg/kg) 
+ ZOL (10 mg/kg)-treated group vs. the value of the Saline + 4 (10 mg/kg)-treated 
group. Data are expressed as mean ± SEM (n=7). 
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4.13 Effects of H3R antagonist 4 on locomotor activity and anxiety levels  
We used the OFT to rule out possible intrinsic impairment of spontaneous 
locomotor activity or anxiety measures. Locomotor activity and anxiety levels were 
measured by the number of line crossings in the arena and time spent in the center or 
periphery in the arena. One-way analysis of variance showed that, compared with 
vehicle, H3R antagonist 4 (2.5, 5, and 10 mg/kg, i.p.), PIT (10 mg/kg, i.p.), and DOZ 
(1 mg/kg, i.p.) had no effect on number of line crossings, [F(5,36) = 0.60, p=0.70] 
(Figure 25A). Similarly, no significant treatment differences were found with regard 
to time spent in the central area or periphery (i.e. level of anxiety) with [F(5,36) = 0.85, 
p=0.52] and [F(5,36) = 0.02, p=0.99], respectively (Figure 25B). 
 
 
 
 
 
Figure  25: Number of line crossing (A) and time spent in center and periphery (B) in 
total area of an open field following acute systemic administration of H3R antagonist 
4. In the open field test, H3R antagonist 4 (2.5, 5 or 10 mg/kg, i.p.) had no effect on 
number of line crossing (A) and time spent in center or periphery (B). Data are 
expressed as mean ± SEM (n=7). 
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Chapter 5: Discussion 
 
Examined compounds 1-12 differed in their chemical structures in the linker 
or spacer lengths (Figure 7) being three, five, or six methylene groups as well as in 
the lipophilic substitution being various groups of known AEDs (Table 3). All 
compounds chosen for the current study have, as previously confirmed, high in vitro 
hH3R affinities with observed pKi values in the range 6.22 to 8.08 (Table 3).  
Table  3: Chemical structures and in vitro antagonist affinities of test compounds 1-12 for 
human histamine H3Rs stably expressed in CHO-K1 cells. 
Compound Structure MWta 
[g/mol] 
hH3R 
pKi
b
 
1  
 
 
499.50
*
 7.37 
2  
 
 
467.25 6.25 
3  
 
 
348.41 6.46 
4  
 
 
379.51 8.08 
5 
 
 
379.49 7.32 
6 
 
 
393.52 7.42 
7 
 
 
393.52 6.81 
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Compound Structure MWta 
[g/mol] 
hH3R 
pKi
b
 
8 
 
 
427.53 7.06 
9 
  
393.52 7.13 
10 
  
407.54 7.07 
11 
 
 
421.53 7.41 
12 
 
 
441.56 6.83 
Pitolisant 
 
385.21 7.57 
a
Molecular weight calculated as hydrogen oxalate. 
b
[
125
I]Iodoproxyfan binding assay at human 
H3R stably expressed in CHO-K1 cells, n = 3. 
*
Molecular weight calculated as dioxalate. 
In the current study, all experiments were conducted with PHT (10 mg/kg, 
i.p), VPA (100 mg/kg, i.p.), or (300 mg/kg, i.p.) in MES-, PTZ- and STR-induced 
seizure models, respectively. These were the minimal doses of PHT and VPA that 
protected animals against MES-, PTZ-, and STR-induced seizures without mortality. 
The test compounds (1-12) varied in their level of protection in the three seizure 
models used in the current study. In MES-induced experiments, H3R antagonists 4, 
8, 10, 11, and 12 showed the best protection against MES-induced (Figure 13) 
convulsion in rats pretreated with 10 mg/kg, i.p. when compared with the saline-
treated group. Accordingly, the anticonvulsant effects obtained were expressed in the 
order of increasing in vivo potency (1 ~ 2 ~ 3 ~ 5 ~ 6 ~ 7 ~ 9 - group I) < (7 ~ 10 ~ 
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11 ~ PIT – group II) < (4 - group III), whereas values for in-vitro H3R affinity 
measured with pKi  values were 2 < 3 < 7 < 12 < 8 < 10 < 9 < 5 < 1 < 11 < 6 < PIT < 
4. It was found that the introduction of a three methylene-spacer together with the 
tert-pentyl moiety significantly increased the lipophilic properties as observed for 
H3R antagonist  4 (c.f. compound 4 vs. 1-3 and 5-12). Such an effect was, also, 
beneficial for the protective in-vivo anticonvulsant effect of H3R antagonist 4 was 
comparable to that observed for the standard H3R antagonist PIT. Interestingly, PIT 
and H3R antagonist 4 incorporate the same structural pharmacophores, namely a 
piperidinylpropyloxy moiety, known to be responsible for H3R antagonist affinity 
(Figure 26). 
 
Figure 26: Structural similarities (red) and differences (blue) between H3R antagonist 
4 and the standard H3R antagonist PIT. 
In contrast, introduction of longer alkyl spacers (5 or 6 methylene groups), 
e.g. H3R antagonists 5-12,  failed to further increase in vitro antagonist affinity for 
hH3Rs as well as to provide higher in vivo protective effects in MES-induced seizure 
model. Nonetheless, it may be concluded that H3R ligands with the 
piperidinylpropyloxy moiety (e. g. PIT and H3R antagonist 4) as a common 
structural feature showed the best protection among the compounds 1–12.  
The results observed in the MES model indicated that H3R antagonist 4 
offered the best protection against MES-induced convulsions when rats were 
pretreated with 10 and 15 mg/kg i.p., as compared with standard H3R antagonist PIT 
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(10 mg/kg, i.p.), the saline-treated group, and the H3R antagonist 4-treated group at a 
dose of 5 mg/kg, i.p (Figure 14). Accordingly, the observed results indicated a dose-
response relationship of the protection observed and the presence of a ceiling for 
H3R antagonist 4 in MES-induced seizures. Notably, the protective effect observed 
for H3R antagonist 4 (10 or 15 mg/kg, i.p.) was comparable to that observed in the 
group pretreated with the reference drug PHT (10 mg/kg, i.p.). Interestingly, these 
results are in agreement with recent studies that described the dose-dependent 
anticonvulsant effect of H3R antagonists in MES-induced seizures in animal models 
and PIT in a photosensitivity seizure model in adult patients (Kasteleijn-Nolst 
Trenite et al., 2013; Sadek et al., 2014a, 2014b, 2013).  Further experiments showed 
that the protective effect of H3R antagonist 4 was reversed when rats were pretreated 
with 10 mg/kg i.p., of the CNS penetrant histamine H1R antagonist PYR 30 min, or 
with the selective H3R agonist R-()-methyl-histamine (RAMH) (10 mg/kg, i.p.) 15 
min before MES challenge (Figure 15). Importantly, PYR (10 mg/kg) and RAMH 
(10 mg/kg) administered alone did not show either a protective or an epileptogenic 
effect in rats challenged by the MES-induced seizure. These findings suggest that the 
protective action of H3R antagonist 4 in the MES-induced seizure is mediated, at 
least partially, through blockade of H3Rs and interactions of released histamine with 
postsynaptically located histamine H1Rs, and these findings are in agreement with 
the previously observed protective effects for H3R antagonists (Kakinoki et al., 
1998; Sadek et al., 2014a). H3Rs are auto-receptors located on presynaptic 
histaminergic terminals with an inhibitory action on the synthesis and release of 
histamine (Arrang et al., 1983). Blockade of these receptors by selective H3R 
antagonists, such as compound 4, would lead to an enhanced neuronal histamine 
release in the brain, resulting in an anticonvulsant effect. Similar effects of 
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imidazole-based as well as non-imidazole-based H3R ligands have been reported 
previously to be reversed either by H3R agonists or by H1R antagonists, but not by 
H2R antagonists, signifying an interaction of the H3R antagonism-released histamine 
with H1Rs on postsynaptic neurons (Bhowmik et al., 2012; Kakinoki et al., 1998; 
Sadek et al., 2014a, 2014b, 2013).  
H3R antagonist 4, on the other hand, failed to offer significant protection 
against chemically (PTZ or STR)-induced seizures (Figure 16 and 19) Notably, PIT 
(10 mg/kg i.p.) had no significant effect in chemically-induced seizures. This could 
be due to differences in the mechanism or type of seizures in each model. 
Accordingly, MES is a model of generalized tonic-clonic seizures (Loscher et al., 
1991a), while PTZ (60 mg/kg, i.p.)  induces generalized myoclonic and/or tonic-
clonic seizures (Loscher et al., 1991b). Moreover, electrically-induced seizures result 
from stimulation of all neuronal pathways and the insult only lasts for a short time 
(one second). However, in chemically-induced seizures, the trigger remains until the 
elimination of the proconvulsant, e.g. PTZ or STR. Furthermore, chemical agents 
affect only some neuronal pathways, e.g. PTZ provides blockage of t-
butylbicyclophosphorothionate (TBPS) site at GABAA receptors (Olsen, 1981) and 
reduces GABA neurotransmission (Corda et al., 1991). It is noteworthy that most 
marketed antiepileptic drugs were not effective in all seizure models. For instance, 
carbamazepine, oxcarbazepine and PHT are highly effective in the MES-induced 
model, however, they lack any protective effects against seizures induced by PTZ, 
STR or picrotoxin (Swinyard et al., 1986, White, 1999). In contrast, ethosuximide 
and tiagabine, which provide high protection in chemically-induced seizure models, 
are inactive in the MES-induced model when used at nontoxic doses (White, 1999). 
These characteristic preclinical activities explain the effectiveness of PHT, 
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carbamazepine and oxcarbazepine but not ethosuximide or tiagabine in patients with 
generalized tonic-clonic seizures. Similarly, H3R antagonist 6 that has no 
pronounced effect in MES test or STR-induced seizures dose dependently suppressed 
PTZ-induced seizures (Figure 17). Notably, H3R antagonist 6 completely abolished 
seizures after acute systemic pretreatment with 10 and 15 mg/kg, and the protection 
observed was similar to that provided by the standard AED VPA 100 mg/kg. 
Interestingly, the protection observed for H3R antagonist 6 in PTZ-induced seizure 
model was partially reversed (Figure 18) upon acute systemic co-administration of 
PYR indicating that part of this effect was H1R-dependent. Other neurotransmitters 
like GABA may be involved in the protective mechanism. It can, also, be 
hypothesized that H3R antagonists could also block histamine H3 heteroreceptors 
that control the release of other neurotransmitters including GABA (Brown et al., 
2001, Haas et al., 2008). In a previous study the H3R antagonist clobenpropit was 
found to increase GABA release and to protect against NMDA-induced 
excitotoxicity in rat cultured cortical neurons (Dai et al., 2007a).  
In a further experiment, H3R antagonists 8 and 11 offered some protection in 
the STR-induced seizure model (Figure 19), however, not as effective as standard 
AED VPA (300 mg/kg, i.p). It is well known that STR is a competitive antagonist of 
the inhibitory amino acid glycine. Consequently, the inability of H3R antagonist 4 to 
protect against STR-induced seizure suggests little or no effect on the glycine 
receptors, since the mechanism underlying STR-induced convulsions is thought to be 
attributed to its blocking effect on glycine receptors in brain as well as in spinal cord 
(Sowemimo et al., 2011).  
Several AEDs negatively influence memory (Hermann et al., 2010). 
Therefore, it is essential to probe such troublesome side effects in novel antiepileptic 
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treatment. Histamine, agents that increase brain histamine (e.g. L-histidine), and H3R 
antagonists have been found to improve different measures of cognition in a plethora 
of preclinical behavioral studies (Table 1) (reviewed by Esbenshade et al., 2008, 
Zlomuzica et al., 2015). Increment of wakefulness and cortical fast rhythms are 
aspects of cognition that have been approved with PIT in the clinics (Dauvilliers et 
al., 2013, Kasteleijn-Nolst Trenite et al., 2013). Several H3R antagonists including 
PIT are currently under clinical investigation for their efficacy in the treatment of 
cognitive disorders (Brioni et al., 2011, Zlomuzica et al., 2015). Since the 
antiepileptic effect observed for H3R antagonist 4 in the MES model depends on its 
histamine neurotransmission modulating effect, the question remained whether such 
central histamine modulation has any impact on memory processes in the same 
animal species. 
 
Figure 27: Chemical structure, in vitro affinities, and in vivo potency of H3R antagonist 
4. 
a
Central histamine H3R assay in vivo after p.o. administration to mice, n=3 (Garbarg et 
al., 1989, Garbarg et al., 1992, Ligneau et al., 1998, Lazewska et al., 2006). 
b
[
125
I]Iodoproxyfan binding assay at human H3R stably expressed in CHO-K1 cells, n=3 
(Ligneau et al., 1994, Ligneau et al., 2000, Lazewska et al., 2006). 
c
[
3
H]Histamine 
binding assay performed with cell membrane preparation of Sf9 cells transiently 
expressing the human histamine H4R and co-expressed with Gαi2 and β1γ2 subunits 
n=3(Meier et al., 2001, Amon et al., 2007, Isensee et al., 2009, Tomasch et al., 2013). 
d
[
3
H]Pyrilamine binding assay performed with cell membrane preparation of CHO-hH1R 
cells stably expressing the human H1R; n=3(Schibli and Schubiger, 2002, van Staveren 
and Metzler-Nolte, 2004). 
e
The affinity for (2)-adrenoceptors was evaluated by 
radioligand binding assays to rats cortex membrane using [
3
H]clonidine (Barbaro et al., 
2002, Betti et al., 2002, Handzlik et al., 2008). 
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Therefore, the non-imidazole-based H3R antagonist 4 with high H3R in vitro 
affinity, excellent in vitro selectivity profile, and in vivo antagonist potency (Figure 
27) has in the current project been investigated for its behavioral effects on 
acquisition, consolidation and retrieval processes in a one-trial inhibitory avoidance 
paradigm in rats. Given that motor activity could mask the effects of H3R antagonist 
4 on learning and memory, we also used an open field test (OFT) to evaluate activity 
and anxiety in the same animals. Memory is often considered to be a process that has 
several stages including acquisition, consolidation, and retrieval (Abel and Lattal, 
2001). Usually, tasks that have been designed to modulate memory processes consist 
of a training session followed, after 24 or more hours, by a test session. In the present 
study, acute systemic administration with 2.5 mg/kg of H3R antagonist 4 enhanced 
memory acquisition when compared with the saline-treated group. However, higher 
doses (5 and 10 mg/kg, i.p.) of H3R antagonist 4 did not affect acquisition, indicating 
that the effect is dose-dependent (Figure 20). The observed dose-dependent 
facilitating effect of H3R antagonist 4 on acquisition is in agreement with a previous 
study in which the reference H3R antagonist GT-2331 showed dose-dependent 
memory-enhancing effects on repeated acquisition in an inhibitory avoidance 
paradigm (Fox et al., 2002). In their study, rats treated with GT-2331 (1 mg/kg, i.p.) 
performed significantly better than those injected with a higher dose (30 mg/kg, i.p.). 
Nonetheless, further behavioral tests should be conducted to investigate whether the 
improving effect of H3R antagonist 4 (2.5 mg/kg) on acquisition is mediated through 
neurotransmission other than histamine, since PYR and ZOL failed to reverse the 
effects of H3R antagonist 4 (Figure 21). In contrast, our results showed that acute 
systemic administration of H3R antagonist 4 in the post-training session failed to 
facilitate consolidation (Figure 22). These results are in disagreement with previous 
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findings highlighting the critical role of H3Rs in consolidation as a stage of memory 
processing (de Almeida and Izquierdo, 1986). Nonetheless, in the latter study 
different animal species and step-down inhibitory avoidance procedures were used 
which could explain the discrepancy between the studies (Bernaerts et al., 2004, 
Charlier et al., 2013). Our results also showed that systemic pre-testing 
administration of H3R antagonist 4 (5 and 10 mg/kg, i.p.) improved memory (Figure 
23), which indicates that this compound when administered at higher doses facilitates 
dose-dependently the retrieval stage. These results for H3R antagonist 4 are in 
agreement with previous studies in which systemic administration of various 
imidazole-based H3R antagonists were found to enhance memory retrieval in a dose-
dependent manner in an object recognition task in rats (Orsetti et al., 2002, Pascoli et 
al., 2009, Bardgett et al., 2010). Interestingly, the procognitive activity of H3R 
antagonist 4 (10 mg/kg, i.p.) on retrieval was in a another experiment completely 
reversed when rats were pretreated with the centrally acting H2R antagonist 
zolantidine (ZOL, 10 mg/kg, i.p.) but not the centrally acting H1R antagonist (PYR, 
10 mg/kg, i.p.), indicating that histaminergic pathways through activation of H2Rs 
appear to be participating in neuronal circuits involved in the retrieval processes 
(Figure 24).  
Importantly, the results observed in the current study for H3R antagonist 4 at 
doses of 2.5, 5, and 10 mg/kg, i.p., did not affect spontaneous locomotor activity and 
anxiety levels of male Wistar rats (Figure 25). This finding is important, since 
improved performance in an inhibitory avoidance task can be the result of numerous 
variables unrelated to memory acquisition such as alterations in spontaneous 
locomotor activity or emotional response (McGaugh and Roozendaal, 2009, Charlier 
et al., 2013). Therefore, it is unlikely that H3R antagonist 4 administered before the 
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conditioning session increased retention through a nonspecific effect during the 
training session. 
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Chapter 6: Conclusion 
 
In conclusion (Figure 28), acute systemic administration of novel and highly 
affine H3R antagonists (1-12) provided different protective effects against in a 
variety of rat seizure models. Through histaminergic-neurotransmission, H3R 
antagonist 4 dose-dependently displayed the greatest anticonvulsant activity in MES-
induced seizures. However, H3R antagonists 6, 8, and 11 provided the highest 
protection in PTZ-, and STR-induced seizure models, respectively. Moreover, acute 
systemic administration of H3R antagonist 4 dose-dependently improved different 
aspects of memory, especially at the level of retrieval. These results enhance further 
Figure  28: Schematic simplified illustration of the study including the most essential 
points regarding  theory, objectives, experiments and concluding remarks.  
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the potential utility of histamine H3R antagonists in the treatment of epilepsy and 
other neuropsychiatric disorders typified by cognitive deficits.  
6.1 Limitations of the study  
- No further experiment were conducted to explain other mechanisms by which 
H3R antagonist 6 protect against PTZ-induced seizures other than the partial 
contribution of H1 receptors. However, possible mechanisms can be deduced 
from the available literature with other H3R antagonists or histamine.  
-  No additional mechanistic experiments were done to understand the pathway 
by which H3R antagonist 4 improve acquisition at 2.5 mg/kg.  
- Based on the main objectives of the study, only one compound of the tested 
H3R antagonists was selected depending on its seizure control and histamine-
driven mechanism of action. The memory effect of other less effective anti-
seizure H3R antagonist can be extrapolated or assumed from H3R antagonist 4 
effects.  
- Due to current unavailability of other optimized memory rat models in our 
laboratory, cognitive effects of H3R antagonist 4 was analyzed based on 
passive avoidance test only.   
6.2 Future direction 
- Explore the behavioral activity of H3R antagonist 4 in other memory models 
for example spatial memory utilizing the Y-maze or the Place recognition test.  
- Test H3R antagonist 4 or other effective compounds like 6, 8 and 11 in other 
seizure  models especially those that represent resistant forms of epilepsy to 
expand the possible therapeutic utility of these compounds and other H3R 
antagonists. 
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- Explore the effects of the most effective anticonvulsant H3R antagonists 1-12  
against low-magnesium- or chemically-induced epileptiform discharges at 
CA1/CA3 regions of hippocampus at the level of brain slices with easier and 
reliable access of compounds. Through this method possible mechanisms of 
beneficial effects can be thoroughly investigated.  
- Further analyze the mechanisms of anticonvulsant activity of H3R 
antagonists through patch-clamp or whole-cell recording in individual isolated 
CA1/CA3 neurons.  
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